(12) STANDARD PATENT (11) Application No. **AU 2017213633 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Enhanced production of immunoglobulins

(51) International Patent Classification(s)
C12N 5/10 (2006.01) ***C12Q 1/68*** (2006.01)
A61K 35/17 (2015.01) ***C40B 40/06*** (2006.01)
A61K 39/395 (2006.01) ***C40B 40/08*** (2006.01)
A61K 47/62 (2017.01) ***C40B 40/10*** (2006.01)
A61K 47/65 (2017.01)

(21) Application No: **2017213633** (22) Date of Filing: **2017.02.03**

(87) WIPO No: **WO17/136734**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/291,217	**2016.02.04**	**US**

(43) Publication Date: **2017.08.10**
(44) Accepted Journal Date: **2023.08.03**

(71) Applicant(s)
Trianni, Inc.

(72) Inventor(s)
Killeen, Nigel;Hasenhindl, Christoph;Duong, Bao

(74) Agent / Attorney
WRAYS PTY LTD, L7 863 Hay St, Perth, WA, 6000, AU

(56) Related Art
WO 02/066618 A1
PRICE, P.W. et al., "Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas", 2009. JOURNAL OF IMMUNOLOGICAL METHODS, Vol.343, No.1, pages 28-41.
AIT-AZZOUZENE, D. et al., "An immunoglobulin C#-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system", 2005. JEM, Vol.201, No.5, pages 817-828.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 August 2017 (10.08.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/136734 A1

(51) International Patent Classification:
C12N 5/10 (2006.01) *C12Q 1/68* (2006.01)
A61K 35/17 (2015.01) *C40B 40/06* (2006.01)
A61K 47/62 (2017.01) *C40B 40/08* (2006.01)
A61K 47/65 (2017.01) *C40B 40/10* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2017/016521

(22) International Filing Date:
3 February 2017 (03.02.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/291,217 4 February 2016 (04.02.2016) US

(71) Applicant: **TRIANNI, INC.** [US/US]; 1515 5th Ave., San Francisco, CA 94122 (US).

(72) Inventors: **KILLEEN, Nigel**; 1515 5th Ave., San Francisco, CA 94122 (US). **HASENHINDL, Christoph**; 1515 5th Ave., San Francisco, CA 94122 (US). **DUONG, Bao**; 1515 5th Ave., San Francisco, CA 94122 (US).

(74) Agent: **BRASHEARS, Sarah**; Convergent Law Group LLP, 475 N. Whisman Road, Suite 400, Mountian View, CA 94043 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

[Continued on next page]

WO 2017/136734 A1

(54) Title: ENHANCED PRODUCTION OF IMMUNOGLOBULINS



FIG. 1C

(57) Abstract: The present invention provides methods and compositions for generating transgenic animals, including transgenic mammals, as well as plasma cells that allow for cell surface capture of secreted immunoglobulin molecules produced endogenously in the plasma cells.

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

ENHANCED PRODUCTION OF IMMUNOGLOBULINS

RELATED APPLICATION

[0001] This application claims priority to USSN 62/291,217, filed February 4, 2016.

FIELD OF THE INVENTION

[0002] This invention relates to production of immunoglobulin molecules, including methods for rapid screening of antigen-specific antibody-secreting cells for the generation of monoclonal antibodies.

BACKGROUND OF THE INVENTION

[0003] In the following discussion certain articles and methods are described for background and introductory purposes. Nothing contained herein is to be construed as an "admission" of prior art. Applicant expressly reserves the right to demonstrate, where appropriate, that the articles and methods referenced herein do not constitute prior art under the applicable statutory provisions.

[0004] Monoclonal antibodies are important biologics that have been widely employed in biomedical research, in clinical diagnostics, and as therapeutic agents because of their exquisite ability to bind antigens of diverse molecular forms. In drug development, monoclonal antibodies are often the molecules of choice because they exhibit desirable pharmacokinetics that are associated with powerful immunological functions normally involved in fending off infectious agents. Furthermore, laboratory animals can readily mount a specific antibody response against any target molecule that is not present natively in the body, making antibody generation a relatively low-risk and cost-efficient approach when compared to alternative strategies.

[0005] Although hybridoma technology was developed more than four decades ago, today it is still the most widely employed technique to generate antigen-specific monoclonal antibodies. In this approach, an animal (typically, a rodent or a rabbit) is first immunized with an antigen of interest. B lymphocytes in the immunized animal that have the receptor specificity for the antigen then become activated, clonally expand, and differentiate into antibody-secreting cells (ASCs). The immunized animal is then sacrificed, and because the ASCs isolated from these animals cannot survive indefinitely in culture, these cells are often immortalized by fusion with malignant plasma cells (such as myeloma or plasmacytoma cells) to generate hybrid

cells called hybridomas. The hybridoma cells are then screened and selected for their ability to secrete antibodies with reactivity to the antigen of interest, often involving multiple rounds of limiting dilution and propagation in culture.

[0006] Alternatively, the ASCs can be individually sorted, and the genes encoding the heavy chain and light chain variable domains (V_H and V_L, respectively) directly cloned without the need to propagate the ASCs *in vitro*. The V_H- and V_L-encoding DNA fragments are next subcloned into an expression vector containing exon sequences for the desired heavy chain and light chain constant regions, respectively. Each V_H and V_L pair of expression vectors are then transfected into a cell line to express the monoclonal antibodies, which are subsequently screened for their ability to recognize the antigen of interest.

[0007] Despite the eventual success in producing monoclonal antibodies against the antigen of interest using either hybridoma or single-cell cloning technique, the efficiency of both techniques is hampered by the labor-intensive process of screening and selection. This is because it has not been feasible to pre-select only the antigen-specific ASCs for fusion with myeloma cells or for single-cell cloning. When B lymphocytes differentiate into ASCs in response to an antigenic encounter, the membrane-bound form of antigen receptors is down-regulated in favor of the secreted form. Thus, selection methods based on the cell surface expression of antigen receptors, such as magnetic or flow-cytometric sorting, do not work well as tools to select for antigen-specific ASCs. Due to this lack of ability to pre-select ASCs, only a small fraction of cells screened in both hybridoma and single-cell cloning techniques produces monoclonal antibodies with specificity for the antigen of interest.

[0008] US patent No. 7,148,040 B2 provides methods to express the membrane-bound form of antigen receptors on hybridoma cells to improve the efficiency of hybridoma screening by selection techniques based on the cell surface expression of antigen receptors. In this approach, myeloma cells are transfected with expression constructs encoding CD79A and CD79B, also known as Igα and Igβ, respectively. CD79A and CD79B are expressed as heterodimers that are necessary for both cell surface expression and signaling functions of the antigen receptors on B cells. As B lymphocytes differentiate into ASCs, they down-regulate CD79A and CD79B expression, thus contributing to the loss of antigen receptor expression on the cell surface. Therefore, re-introducing the expression of CD79A and CD79B allows for

increased representation of the membrane-bound form of antigen receptors on the hybridomas. Although this strategy helps reduce the labor of hybridoma screening and selection, the efficiency could be greatly improved if it was feasible to pre-select only the antigen-specific ASCs for fusion with myeloma cells. Moreover, the specified methods do not provide a strategy to increase the efficiency of monoclonal antibody generation using direct V_H and V_L cloning technique from sorted single cells.

[0009] Re-introduction of CD79A and CD79B expression by ASCs *in vivo* may not provide a viable strategy to increase the expression of antigen receptors on the cell surface either. Because CD79A and CD79B expression is tightly regulated during B lymphocyte development, alterations in their expression levels *in vivo* may have profound consequences on B lymphocyte survival, functions, and/or antigen receptor selection. Moreover, the antigen receptors on ASCs are likely to be internalized at the time of ASC isolation due to their active engagement with the immunogen, since the immune response is still ongoing when the mouse is euthanized. If instead, signaling-deficient mutant CD79A and CD79B are expressed on ASCs to prevent antigen receptor internalization, it remains unexplored whether the mutant forms of these molecules exhibit a dominant-negative effect that negatively impacts ASC survival and functions *in vivo*. Finally, expressing CD79A and CD79B on ASCs *ex vivo* to circumvent the aforementioned problems associated with their enforced expression *in vivo* is not a practical strategy because ASCs are not amenable to gene transfer by most methods currently available.

[00010] Thus, a method for more efficient screening for antigen-specific ASCs is an important unmet need. The methods and compositions provided by the present specification meet this important need.

SUMMARY OF THE INVENTION

[00011] This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. Other features, details, utilities, and advantages of the claimed subject matter will be apparent from the following written Detailed Description including those aspects illustrated in the accompanying drawings and defined in the appended claims.

[00012] The present invention provides methods and compositions for enhanced production of immunoglobulin molecules. Specifically, the invention provides methods and compositions for the capture of secreted immunoglobulin molecules, including those of IgG, IgA, IgE and IgM isotypes, at the surface of ASCs. The present invention also comprises transgenic animals, including transgenic mammals, comprising engineered ASCs that can capture and display on their cell surface immunoglobulin molecules produced endogenously from within the ASCs.

[00013] In one embodiment, the invention provides restricted constitutive expression of an engineered immunoglobulin-capturing molecule comprising one or more immunoglobulin-binding portions or domains derived from bacterial protein(s) such as Protein A and/or Protein G, using an expression system that expresses the immunoglobulin-capturing molecule preferentially on ASCs with minimal expression at the stages of B cell development prior to antigen-induced differentiation.

[00014] In another embodiment, the invention provides restricted constitutive expression of an engineered immunoglobulin-capturing molecule comprising a single-chain antibody with specificity to an immunoglobulin, using an expression system that expresses the immunoglobulin-capturing molecule preferentially on ASCs with minimal expression at the stages of B cell development prior to antigen-induced differentiation.

[00015] The engineered ASCs express immunoglobulin-capturing molecules that are tethered to the cell surface and have the ability to selectively bind immunoglobulin molecules (also, as used herein "immunoglobulins" or "antibodies") with sufficient affinity to immobilize the immunoglobulin molecules at the plasma membrane. Because ASCs secrete thousands of immunoglobulin molecules per second, the immunoglobulin-capturing molecules on a given ASC are saturated primarily with the

immunoglobulin molecules secreted by that ASC rather than with immunoglobulins secreted by other ASCs. Expression of genes encoding cell surface immunoglobulin-capturing molecules provides a means for identifying ASCs based on the particular monoclonal immunoglobulin molecules being expressed.

[00016] In certain aspects, the immunoglobulin-capturing molecule is tethered to the membrane by a peptide sequence derived from a transmembrane protein such as but not limited to human Lymphocyte-Activation Gene 3 (LAG3). In other aspects, the immunoglobulin-capturing molecule is tethered to the plasma membrane via a post-translational modification with, *e.g.*, glycosylphosphatidylinositol (GPI). In some of these aspects, the immunoglobulin-capturing molecule further comprises a long stalk for support, flexibility, and extended protrusion into the extracellular space.

[00017] In certain aspects, expression of the immunoglobulin-capturing molecules is driven by a promoter derived from a human or mouse gene that is highly expressed in ASCs developed *in vivo* or *in vitro*. In other aspects, the immunoglobulin-capturing molecules are expressed by an inducible system, such as the tetracycline system, *in vivo* or *in vitro*. In some aspects, expression of the immunoglobulin-capturing molecule is coupled to the expression of a reporter gene, such as green fluorescent protein (GFP), via an internal ribosomal entry site sequence (IRES) or a picornavirus 2A ribosomal skip sequence in the expression vector.

[00018] The present invention also provides methods for generating a non-human transgenic animal expressing immunoglobulin-capturing molecules on ASCs. The methods comprise introducing an immunoglobulin-capturing molecule-encoding gene into the genome of a non-human vertebrate, wherein the introduced gene provides constitutive or inducible expression of the immunoglobulin-capturing molecule on host ASCs. In some aspects the transgenic animal is a rodent, preferably a mouse. In other aspects, the transgenic animal is avian, preferably a chicken. In particularly preferred aspects, the transgenic animal is a mouse that expresses human genes encoding the variable domains of the heavy and light chains and lacks the mouse versions of these genes; for example, as described in US Pub. No. 2013/0219535, which is incorporated by reference in its entirety.

[00018a] In one aspect of the present invention, there is provided a method for generating an antibody-secreting cell capable of expressing a membrane-bound immunoglobulin-capturing molecule that can bind, retain, and display endogenously produced immunoglobulin molecules at its cell surface, comprising the step of:

introducing into the antibody-secreting cell, or the progenitor of an antibody-secreting cell, a nucleic acid vector, wherein the nucleic acid vector comprises a promoter operably connected to a nucleic acid sequence; wherein the nucleic acid sequence encodes an immunoglobulin-capturing molecule comprising an immunoglobulin-binding portion and a cell surface tether portion; wherein the cell surface tether portion comprises a transmembrane peptide or a C-terminal peptide sequence that can be post-translationally modified to tether the immunoglobulin-binding portion to the cell surface of the antibody-secreting cell; and wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin.

[00018b] In a further aspect of the present invention, there is provided a genetically modified rodent comprising antibody-secreting cells comprising an exogenous nucleic acid sequence comprising: a promoter, that is expressed in the antibody-secreting cells; and a nucleic acid sequence encoding an immunoglobulin-capturing molecule comprising a cell surface tether portion and an immunoglobulin-binding portion, wherein the promoter is operably linked to the nucleic acid sequence encoding the immunoglobulin-capturing molecule; wherein the cell surface tether portion comprises a transmembrane peptide or a C-terminal peptide sequence that can be post-translationally modified to tether the immunoglobulin-binding portion to the cell surface of the antibody-secreting cell; wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin; and wherein the antibody secreting cells of the genetically modified rodent are capable of producing immunoglobulin-capturing molecules that can bind, retain, and display endogenously produced immunoglobulin molecules at a cell surface of the antibody- secreting cells.

[00018c] In yet a further aspect of the present invention, there is provided a vector for expressing a membrane-bound immunoglobulin-capturing molecule that can bind, retain, and display immunoglobulin molecules at a cell surface of an antibody-

secreting cell, comprising a promoter operably connected to a nucleic acid sequence, wherein the nucleic acid sequence encodes an immunoglobulin-capturing molecule comprising an immunoglobulin-binding portion and a cell surface tether portion; wherein the cell surface tether portion comprises a transmembrane peptide or a C-terminal peptide sequence that can be post-translationally modified to tether the immunoglobulin-binding portion to the cell surface of the antibody-secreting cell; and wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin, wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin; and wherein the antibody secreting cells of the genetically modified rodent are capable of producing immunoglobulin-capturing molecules that can bind, retain, and display endogenously produced immunoglobulin molecules at a cell surface of the antibody- secreting cells.

[00019] The invention additionally provides processes for isolating genes that encode immunoglobulins of a particular specificity from ASCs that display the specific immunoglobulins captured on the surface of the ASCs.

[00020] The present invention also provides libraries for identification of antibodies of

[Text continued on page 6]

interest from the engineered cells of the invention. The antibody libraries produced using the methods and compositions of the invention provide a facilitated means for the screening and production of antibodies that selectively bind to a target of interest. Such libraries thus enhance the isolation of monoclonal antibodies for use in the clinical, diagnostic, and research settings.

[00021] An advantage of the invention is that the determination of immunoglobulin specificity can be made using established techniques such as binding to fluorescently labeled antigen and flow cytometric or microscopic procedures. Such procedures allow for enhanced efficiency in identification and isolation of rare antigen-specific cells and the cloning of the rearranged immunoglobulin genes from the isolated cells.

[00022] These and other aspects, objects and features are described in more detail below.

BRIEF DESCRIPTION OF THE FIGURES

[00023] **Figures 1A, 1B and 1C** are illustrations of a secreting ASC with no immunoglobulin-capturing molecules on the cell surface (**Figure 1A**), an ASC with immunoglobulin-capturing molecules and captured immunoglobulin molecules (*i.e.*, antibodies) on the surface of the ASC (**Figure 1B**), and the binding of labeled antigens to the antibodies retained by the immunoglobulin-capturing molecules expressed on an ASC (**Figure 1C**).

[00024] **Figure 2A** is a schematic diagram depicting part of a DNA vector encoding an embodiment of an immunoglobulin-capturing molecule. **Figure 2B** is a simplified illustration of the embodiment of Figure 2A expressed as an immunoglobulin-capturing molecule on an ASC surface.

[00025] **Figure 3A** is a schematic diagram depicting part of a DNA vector encoding an alternative embodiment of an immunoglobulin-capturing molecule. **Figure 3B** is a simplified illustration of the embodiment of Figure 3A expressed as an immunoglobulin-capturing molecule on an ASC surface.

[00026] **Figure 4A, 4B, and 4C** are illustrations of a secreting ASC with no immunoglobulin-capturing molecules on the cell surface (**Figure 4A**), an ASC with immunoglobulin-capturing molecules and immunoglobulins (*i.e.*, antibodies) on the surface of the ASC (**Figure 4B**, also as depicted in detail in Figure 3B), and labeled

2017213633 30 Jun 2023

antigens bound to the immunoglobulin-capturing molecules expressed on an ASC (**Figure 4C**).

[00027] **Figure 5A** is a schematic diagram depicting part of a DNA vector encoding an exemplary embodiment of an immunoglobulin-capturing molecule. **Figure 5B** provides two flow cytometry scatter plots showing the results of retention of secreted immunoglobulin molecules on the cell surface of transfected RPMI 8226 (ATCC® CCL-155™) human cells per the methods of the invention.

DEFINITIONS

[00028] The terms used herein are intended to have the plain and ordinary meaning as understood by those of ordinary skill in the art. The following definitions are intended to aid the reader in understanding the present invention, but are not intended to vary or otherwise limit the meaning of such terms unless specifically indicated.

[00028a] Throughout the specification and claims, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

[00029] An "antibody-secreting cell" or "ASC" refers to a cell that has differentiated from an antigen-experienced B cell and acquired the capacity to express as well as secrete large amounts of immunoglobulin molecules. ASCs include plasmablasts and short-lived or long-lived plasma cells in the animal, as well as plasmablasts and plasma cells developed *in vitro* from B cell cultures.

[00030] A "capture molecule" is any moiety that contains a region that selectively binds to a part of or a whole molecule of interest.

[00031] "Capture" refers to selective binding and immobilization of a molecule at a cell surface due to a durable interaction between that molecule and a membrane-bound capture molecule.

[00032] "Cell surface" refers to the plasma membrane of a cell, *i.e.*, that part of a cell most directly exposed to extracellular spaces and available for contact both with cells and proteins in the extracellular (including intercellular) space.

[00033] An "immature B cell" refers to a cell at an intermediate phase of B cell differentiation, during which a hematopoietic stem cell undergoes genetic programming to become a mature, yet antigen-inexperienced, B cell. A "mature" B cell refers to an antigen-inexperienced B cell, which is capable of clonal expansion, as well as differentiation into a memory cell or an antibody-secreting cell, upon activation by an antigen.

[00035] An "immunoglobulin" refers to an antibody, whether a part of or whole antibody molecule. In most vertebrate animals including humans, antibodies

normally exist as dimers of two identical heavy (H) chains that are each paired with an identical light (L) chain. The N-termini of both H and L chains consist of a variable domain (V_H and V_L, respectively) that together provide the H-L pair with its unique antigen-binding specificity. The constant region of the H chain consists of 3 to 4 immunoglobulin domains (referred to as C_H1 to C_H4) with or without a hinge, depending on the isotype (or antibody class). In mice, the isotypes are IgM, IgD, IgG3, IgG1, IgG2b, IgG2a or IgG2c, IgE, and IgA. The light chain constant region consists of either a κ or λ immunoglobulin domain (referred to as Cκ or Cλ). In both mice and humans, the presence of κ light chains predominates over that of λ light chains in the total pool of immunoglobulins within an individual. In certain mammals, such as camelids or animals made deficient in light chain expression, immunoglobulins may consist of heavy chains only. Despite the lack of light chains, these immunoglobulins are also efficiently retained on the cell surface by immunoglobulin-capturing molecules designed to bind to the immunoglobulin heavy chain described in the present invention. Additionally, an immunoglobulin can refer to an unconventional antibody, whether in part or in whole, such as a bispecific antibody that consists two or more V_H and/or V_L domains, for example, as described in USSN 15/246,181, filed 24 August 2016, which is incorporated by reference in its entirety. Finally, an immunoglobulin also refers to a hybrid molecule consisting of part of an antibody, particularly the antibody constant region, and part of another protein. The immunoglobulin-capturing molecules described in the present invention also may be designed and engineered to retain hybrid immunoglobulin molecules for display at the cell surface.

[00035] An "immunoglobulin-capturing molecule" refers to a plasma membrane-bound molecule that can bind, retain, and display immunoglobulin molecules (*i.e.*, immunoglobulins or antibodies) at the cell surface.

[00036] An "immunoglobulin superfamily" or "IgSF" molecule refers to a molecule that possesses immunoglobulin folds (Ig folds) that are structurally similar to the immunoglobulin domains found in antibody molecules.

[00037] The term "transgene" is used herein to describe genetic material which has been or is about to be artificially inserted into the genome of a cell.

[00038] "Transgenic animal" refers to a non-human animal, usually a mammal such as a rodent, particularly a mouse or rat although other animals are envisioned, having an

exogenous nucleic acid sequence present as a chromosomal or extrachromosomal element in a portion of its cells or stably integrated into its germ-line DNA (*i.e.*, in the genomic sequence of most or all of its cells).

[00039] A "vector" or "expression construct" includes plasmids and viruses and any DNA or RNA molecule, whether self-replicating or not, which can be used to transform, transduce, or transfect a cell.

DETAILED DESCRIPTION OF THE INVENTION

[00040] The practice of the techniques described herein may employ, unless otherwise indicated, conventional techniques and descriptions of organic chemistry, polymer technology, molecular biology (including recombinant techniques), cell biology, biochemistry, and sequencing technology, which are within the skill of those who practice in the art. Such conventional techniques include polymer array synthesis, hybridization and ligation of polynucleotides, and detection of hybridization using a label. Specific illustrations of suitable techniques can be had by reference to the examples herein. However, other equivalent conventional procedures can, of course, also be used. Such conventional techniques and descriptions can be found in standard laboratory manuals such as Green, et al., Eds. (1999) *Genome Analysis: A Laboratory Manual Series* (Vols. I-IV); Weiner, Gabriel, Stephens, Eds. (2007), *Genetic Variation: A Laboratory Manual*; Dieffenbach, Dveksler, Eds. (2007), *PCR Primer: A Laboratory Manual*; Sambrook and Russell (2006), *Condensed Protocols from Molecular Cloning: A Laboratory Manual*; and Green and Sambrook (2012), *Molecular Cloning: A Laboratory Manual* (all from Cold Spring Harbor Laboratory Press); Stryer, L. (1995) *Biochemistry* (4th Ed.) W.H. Freeman, New York N.Y.; Lehninger, *Principles of Biochemistry* 3rd Ed., W. H. Freeman Pub., New York, N.Y.; and Berg et al. (2002) *Biochemistry*, 5th Ed., W.H. Freeman Pub., New York, N.Y.; Nagy, et al., Eds. (2003) *Manipulating the Mouse Embryo: A Laboratory Manual* (3rd Ed.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., *Immunology Methods Manual* (Lefkovits ed., Academic Press 1997); *Gene Therapy Techniques, Applications and Regulations From Laboratory to Clinic* (Meager, ed., John Wiley & Sons 1999); M. Giacca, *Gene Therapy* (Springer 2010); *Gene Therapy Protocols* (LeDoux, ed., Springer 2008); *Cell and Tissue Culture: Laboratory Procedures in Biotechnology* (Doyle & Griffiths, eds., John Wiley & Sons 1998); and *Mammalian Chromosome Engineering – Methods and Protocols* (G.

Hadlaczky, ed., Humana Press 2011), all of which are herein incorporated in their entirety by reference for all purposes.

[00041] Note that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an immunoglobulin” refers to one or more such immunoglobulins, and reference to “the method” includes reference to equivalent steps and methods known to those skilled in the art, and so forth.

[00042] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing devices, formulations and methodologies that may be used in connection with the presently described invention.

[00043] Where a range of values is provided, it is understood that each intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[00044] In the following description, numerous specific details are set forth to provide a more thorough understanding of the present invention. However, it will be apparent to one of skill in the art that the present invention may be practiced without one or more of these specific details. In other instances, well-known features and procedures well known to those skilled in the art have not been described in order to avoid obscuring the invention.

The Invention in General

[00045] Antibody-secreting cells (ASCs) normally do not display the immunoglobulins they express and secrete on their plasma membrane, making highly advanced techniques based on cell surface labeling, such as magnetic and flow-cytometric sorting, inapplicable as methods to select for antigen-specific ASCs. The present invention was born out of the need for a system that allows for efficient screening of ASCs based on cell surface presentation of secreted immunoglobulin molecules (also

as used herein "immunoglobulins" or "antibodies"). Specifically, the present invention provides a means for expressing immunoglobulin-capturing molecules that can retain and immobilize immunoglobulins at the surface of the secreting cells, such as ASCs or hybridomas, which do not normally express high levels of membrane-bound immunoglobulins or naturally have the ability to retain immunoglobulins on their cell surface. ASCs express and release large amounts of immunoglobulins (thousands of molecules per second) (see, *e.g.*, Mitchell, *Advances in Immunology* 28:451-511 (1979)). Therefore, the immunoglobulin-capturing molecules expressed on these cells are saturated primarily with immunoglobulins produced from within, rather than with the immunoglobulins secreted by other cells. Thus, the immunoglobulin-capturing molecules must possess a high affinity and a low dissociation rate for the immunoglobulin molecules they capture. The present invention provides methods and compositions for expression of such high-affinity immunoglobulin-capturing molecules with low dissociation rates.

[00046] Engineering ASCs to capture endogenously produced immunoglobulins on their cell surface provides a facile means for discriminating the antigen specificity of the antibodies that each ASC produces, and for separating ASCs secreting desired immunoglobulins from those ASCs that do not. Discrimination can be accomplished by, *e.g.*, using antigens labeled with substances that facilitate identification and purification of cells (*e.g.*, magnetic, biotinylated, fluorescent, radioactive, or enzymatic molecules) by well-established procedures known in the art.

[00047] Figures 1A, 1B and 1C illustrate the principles of the present invention in one exemplary embodiment. As depicted in Figure 1A, an antibody-secreting cell (ASC) (101) does not normally express the membrane-bound form of the immunoglobulin molecule, nor does it retain the secreted form of the immunoglobulin molecule (*i.e.*, antibody) (102) on its cell surface. The present invention provides methods and compositions for the expression of immunoglobulin-capturing molecules (103) on the cell surface of ASCs. According to the invention, during the synthesis of the immunoglobulin molecules in the endoplasmic reticulum and subsequent packaging in the vesicles for secretion—or soon after their secretion—some immunoglobulin molecules (102) are retained on the cell surface by immunoglobulin-capturing molecules (103) as depicted in Figure 1B. Labeled antigens (104) (*e.g.*, fluorescently-labeled antigens) are then allowed to bind to the immunoglobulin molecules (antibodies) (102) that have bound to an immunoglobulin-binding portion of the

immunoglobulin-capturing molecules (103) on the cell surface of the ASC, as depicted in Figure 1C. Antigen-specific ASCs are then identified by the labeled antigens (104) bound to the immunoglobulin-binding portion of the immunoglobulin-capturing molecules (102) that have been captured on the cell surface. Detection of antigen binding on the ASCs is accomplished by, *e.g.*, using antigens that are directly labeled with a fluorophore or other reporter molecule. The ASCs that bind labeled antigens are then purified by, *e.g.*, cell-sorting techniques known in the art.

[00048] The purified ASCs expressing antibodies specific for a particular antigen may then be immortalized by fusion with myeloma or plasmacytoma cells, or directly used as a source of nucleic acids (DNA or mRNA) for the creation of libraries of sequences encoding immunoglobulins.

[00049] Libraries from purified ASCs contain rearranged immunoglobulin genes encoding antibodies of defined specificity (*i.e.*, specificity for the antigens used in the purification process). The V_H and V_L genes can be identified from the antigen-specific ASCs by deep sequencing coupled with bioinformatics data mining (see, *e.g.*, Haessler and Reddy, Methods in Molecular Biology 1131:191-203 (2014)). Alternatively, the antigen-specific ASCs can be individually sorted. The V_H and V_L domains unique to each ASC are then cloned via established RT-PCR or 5' Rapid Amplification of cDNA Ends (5' RACE) techniques adapted to single-cell cloning (for review, see, *e.g.*, Tiller, et al., New Biotechnology 5:453-7 (2011)). In yet another alternative, the V_H and V_L sequences can be identified using the methods and materials described in US Pat. Nos. 9,328,172; 8,309,035; and 8,309,317.

The Immunoglobulin-capturing molecule

[00050] The immunoglobulin-capturing molecules of the present invention that are expressed at the cell surface comprise at least two components, and in preferred embodiments may comprise additional components, as described in detail below. In a simple form, the immunoglobulin-capturing molecules comprise a cell surface tether component, and an immunoglobulin-binding component. The cell surface tether component may comprise a transmembrane peptide domain that tethers or anchors the expressed immunoglobulin-binding component in the cell surface membrane, or the cell surface tether component may comprise a chemical moiety (for example, glycosylphosphatidylinositol) that allows for the immunoglobulin-binding component to be tethered to the cell surface membrane via a chemical bond. In addition to these

components, the immunoglobulin-capturing molecules of the present invention may comprise a stalk component, one or more linker components, and/or a reporter peptide.

[00051] In one embodiment, the immunoglobulin-capturing molecule consists of one or more immunoglobulin-binding domains or portions derived from one or more bacterial proteins that naturally have affinity for the constant region of the heavy or light chain of immunoglobulins. Such immunoglobulin-binding proteins include but are not limited to Protein A from *Staphylococcus aureus*, Protein G from group C and G *Streptococci*, Protein H from *Streptococcus pyogenes*, or Protein L from *Peptostreptococcus magnus*. In some embodiments, the immunoglobulin-capturing molecule is expressed as a hybrid molecule comprising two or more immunoglobulin-binding domains derived from two or more different bacterial proteins. As an example, the capture molecule may be expressed as a fusion protein, which contains two immunoglobulin-binding domains from Protein G and two immunoglobulin-binding domains from Protein A. In some aspects of this embodiment, one or more of the bacterial immunoglobulin-binding protein domains are modified to, *e.g.*, remove potential sites for glycosylation or other post-translational modifications in eukaryotic cells, improve affinity for certain immunoglobulin isotypes, or improve translation efficiency in mammalian cells by codon optimization.

[00052] In another embodiment, the immunoglobulin-capturing molecules consist of single-chain variable fragments (scFv). The scFv is expressed as a fusion protein of the V_H and V_L domains derived from a hybridoma cell line that produces monoclonal antibodies against the heavy chain or light chain constant region of another immunoglobulin molecule (*e.g.*, a common epitope present in all murine IgG isotypes). In some aspects, the scFv capture molecule comprises the V_H domain connected in tandem to the V_L domain by a glycine/serine-rich linker sequence in either order. The glycine/serine-rich linker sequence includes but is not limited to repetitions of $(Gly\text{-}Gly\text{-}Gly\text{-}Gly\text{-}Ser)_n$ [as in SEQ ID No. 29] or $(Gly\text{-}Ser)_n$ [as in SEQ ID No. 28].

[00053] In some embodiments, a polypeptide sequence encoding a transmembrane domain is fused to the immunoglobulin-binding domain in order to tether the immunoglobulin-capturing molecule on the cell surface. Preferably in this embodiment, the transmembrane domain is inert (lacking cell signaling functions) and not prone to internalization. Such a transmembrane domain could be an artificial

sequence, or a motif derived from Major Histocompatibility Class I (MHC I), an IgSF molecule such as Lymphocyte-Activation Gene 3 (LAG3 or CD223), or any other transmembrane protein of any species—that is naturally inserted into the plasma membrane upon protein translation.

[00054] In other embodiments, the immunoglobulin-capturing molecule contains—in addition to the immunoglobulin-binding domain—a C-terminal peptide sequence for post-translational modification with, *e.g.*, glycosylphosphatidylinositol (GPI), where GPI acts as a tether portion of the immunoglobulin-capturing molecule. GPI is a normal post-translational moiety that comprises a phosphoethanolamine group, a trimannosyl-nonacetylated glucosamine (Man_3-GlcN) core, and a phosphatidylinositol group that tethers the protein to the plasma membrane. The phosphoethanolamine group of GPI is linked to a protein C-terminus via a phosphodiester bond. The GPI tether sequences may consist of the C-termini of proteins that are naturally anchored to the ASC plasma membrane by this post-translational process. Table 3 lists exemplary GPI tether or anchor sequences that may be used to construct the immunoglobulin-capturing molecule.

[00055] In certain embodiments, the immunoglobulin-capturing molecule contains a "stalk" structure for structural flexibility and support, as well as for increased exposure to the extracellular space. Since the cell surface is ubiquitously crowded with various molecules, the immunoglobulins captured on the immunoglobulin-capturing molecules may be occluded from access to their cognate antigen in the extracellular space by other molecules on the ASC surface. Thus, inclusion of a long stalk in the immunoglobulin-capturing molecule can alleviate any steric hindrance that compromises antigen binding by the displayed immunoglobulins. In preferred aspects of the invention, the stalk of the immunoglobulin-capturing molecule comprises one or more immunoglobulin domains derived from one or more IgSF proteins. Examples of these domains include but are not limited to the immunoglobulin domains of CD2, CD4, or CD22. Additionally, the stalk of the immunoglobulin-capturing molecule may be expressed as a macromolecular complex of two or more subunits. For example, the stalk of the ScFv-containing capture molecule may consist of C_H2 and C_H3 domains as well as the hinge region of an IgG molecule; thus, the immunoglobulin-capturing molecule is expressed as a homodimer.

Expression of the immunoglobulin-capturing molecule

[00056] In certain aspects of the invention, expression of the immunoglobulin-capturing molecules is driven by a promoter derived from a gene that is highly expressed in ASCs but not in immature B cells or antigen-inexperienced mature B cells. These genes include but are not limited to *B Lymphocyte-Induced Maturation Protein 1* (*Blimp1*), *Syndecan 1* (*Sdc1*), *Tumor Necrosis Factor Receptor Superfamily Member 17* (*Tnfrsf17*), and *Fucosyltransferase 1* (*Fut1*). The gene chosen for ASC expression may be of mouse origin, or it may be from another species in which the gene shows an appropriately conserved expression pattern.

[00057] In certain other aspects, expression of the immunoglobulin-capturing molecules is driven by an inducible promoter, such as the tetracycline- or tamoxifen-inducible system. The inducible promoter is used to drive the expression of the immunoglobulin-capturing molecule either directly or indirectly via expression of a recombinase such as Cre (see, *e.g.*, Albanese, et al., *Seminars in Cell & Developmental Biology*, 13:129–141 (2002); Sakai, *Methods in Molecular Biology*, 1142:33-40 (2014)). Such inducible expression in ASCs is accomplished either in the transgenic animal or *in vitro* during culture of ASCs as well as at the stage of hybridoma culture.

[00058] In order to express the immunoglobulin-capturing molecule on the cell surface, a signal peptide is included for protein translation in the endoplasmic reticulum. The signal peptide may be a consensus sequence or one that naturally exists as part of cell surface or secreted protein. In preferred aspects of the invention, the signal peptide is derived from that of an immunoglobulin heavy chain [as in SEQ ID Nos. 5-7] or light chain protein [as in SEQ ID Nos 1-3].

[00059] In some aspects, in addition to the immunoglobulin-capturing molecule, the expression vector may include an open-reading frame for a reporter protein such as GFP, red fluorescent protein (RFP), or the like. The reporter gene in the expression construct is linked to the immunoglobulin-capturing molecule via, *e.g.*, an IRES sequence or a picornavirus 2A ribosomal skip sequence. Expression of the reporter gene allows for improved purity when used in combination with antigen selection to sort for antigen-specific ASCs.

[00060] Transgenes providing for expression of the immunoglobulin-capturing molecules are generated by inserting the coding sequences for the immunoglobulin-capturing molecules into a large piece of genomic DNA containing the gene that is highly expressed in ASCs (*e.g, Blimp1* or *Tnfrsf17*). The insertion can be

accomplished by homologous recombination mediated by sequences appended to the ends of the coding fragments, or by other standard molecular biology approaches. The large pieces of genomic DNA may be contained within bacterial artificial chromosome vectors, *e.g.*, such as the pieces of DNA in these vectors that can be obtained from commercially or publicly available genomic DNA libraries.

[00061] Transgenic mice (or other animals) expressing the immunoglobulin-capturing molecules may be generated by any facility with the requisite skills using known techniques, as will be understood by one skilled in the art upon reading the present disclosure. Analysis of the animals carrying the transgene is performed using standard methodology such as immunofluorescence microscopy, flow cytometry and/or immunoblotting.

[00062] Illustrated in Figures 2A and 2B are the transgene (201) and expressed structure (202) of an immunoglobulin-capturing molecule according to one embodiment. The transgene (201) comprises two exons with an intervening intron (203) [SEQ ID Nos. 5-7]. The first exon and the beginning of the second exon encode a leader peptide (*e.g.*, V_H leader peptide). Contiguous with the leader peptide-encoding sequence are sequences encoding the following components: one or more immunoglobulin-binding domains (204) derived from one or more bacterial proteins [*e.g.*, a sequence chosen from SEQ ID Nos. 8-11], a glycine/serine-rich linker (205) [*e.g.*, a sequence chosen from SEQ ID Nos. 12 or 13], a "stalk" structure or region (206) [*e.g.*, a sequence chosen from SEQ ID Nos. 14-16], and a transmembrane domain (207) [*e.g.*, a sequence chosen from SEQ ID No. 17-20]. Following protein translation, the leader peptide is excised from the immunoglobulin-capturing molecule (202), which is expressed as a cell surface protein tethered to the plasma membrane (212). The respective components (208-211) of the immunoglobulin-capturing molecule (202) shown are immunoglobulin-binding domain(s) (208) [*e.g.*, a sequence chosen from SEQ ID Nos. 24-27], glycine/serine-rich linker (209) [*e.g.*, a sequence chosen from SEQ ID Nos. 28 or 29], stalk (210) [*e.g.*, a sequence chosen from SEQ ID Nos. 30-32], and transmembrane domain (211) [*e.g.*, a sequence chosen from SEQ ID Nos. 33-36].

[00063] Exemplary nucleic acid sequences for components of the immunoglobulin-capturing molecule illustrated in Figure 2A (with the expressed structure illustrated in Figure 2B) are listed in Table 1. The immunoglobulin-capturing molecule may be assembled by combining together one sequence of the several possible options for

each component from Table 1 in the order depicted in Figure 2A (*i.e.*, from N-terminus to C-terminus). For example, a small immunoglobulin-capturing molecule may consist of only two immunoglobulin-binding domains of Protein G, a (glycine-serine)$_3$ linker, and a transmembrane domain without a stalk; while a larger one may contain five Protein A immunoglobulin-binding domains as well as four Protein G immunoglobulin-binding domains, a (Gly-Gly-Gly-Gly-Ser)$_3$ linker, a human CD22 stalk composed of six immunoglobulin folds, and a long human CD7 transmembrane domain.

[00064] An expression construct and the molecular structure of an alternative embodiment of an immunoglobulin-capturing molecule is illustrated in Figures 3A and 3B. In this embodiment of the invention, the transgene (301) similarly comprises a leader sequence encoded by two exons with an intervening intron (303), followed by sequences encoding the components of a scFv with specificity for a part of an immunoglobulin molecule (*e.g.*, a conserved part of the heavy or light chain constant region): V_H (304), glycine/serine-rich linker (305), and V_L (306). For extended protrusion of the immunoglobulin-capturing molecule into the extracellular space, a sequence encoding a stalk comprising a hinge (307) as well as Fc fragment (308) of an immunoglobulin molecule is appended to the scFv-encoding sequence. Finally, one or more exons (309) encoding a transmembrane domain is also included in the expression construct (301). Shown in Figure 3B is the immunoglobulin-capturing molecule (302) expressed as a homodimer of two subunits, each consisting of a V_L (310) domain, glycine/serine-rich linker (311), and V_H (312) domain of scFv connected to a hinge (313) and Fc (314) of an immunoglobulin molecule. The two subunits of the immunoglobulin-binding portion of the immunoglobulin-capturing molecule are covalently linked via disulfide bonds in the hinge region (313) of each chain. The expressed immunoglobulin-capturing molecule is tethered or anchored into the plasma membrane (316) by a transmembrane domain (315).

[00065] Figure 4 illustrates the presentation of immunoglobulin-capturing molecules on a cell surface by an scFV embodiment of the immunoglobulin-capturing molecule. As demonstrated previously, an antibody-secreting cell (401) normally does not express the membrane-bound form of antigen receptors and lacks the ability to display on the cell surface the immunoglobulin molecules (402) they secrete. Expression of the scFv version of the immunoglobulin-capturing molecule (403) allows some of the immunoglobulin molecules (402) to be retained on the cell surface as they are being

synthesized in the endoplasmic reticulum and subsequently packaged in the vesicles for secretion, or soon after their secretion. Antigen-specific ASCs are then identified by the binding of antigens (404) to the captured immunoglobulin molecules (402) on the cell surface. Detection of antigen binding on the ASCs is accomplished by using antigens that are directly labeled with a fluorophore or any other reporter molecule.

Transgenic Cell Libraries

[00066] The transgenic cells of the invention also are used to produce expression libraries, preferably low complexity libraries, for identification of antibodies of interest on the surface of ASCs. The present invention thus also includes antibody libraries produced using the cell technologies of the invention for identification of antigen-specific antibodies expressed on ASCs.

Transgenic Animals

[00067] The present invention also provides transgenic animals that have been modified to express immunoglobulin-capturing molecules on the cell surface of ASCs.

[00068] In preferred aspects, the transgenic animals of the invention further comprise human immunoglobulin regions. Numerous methods have been developed for replacing endogenous mouse immunoglobulin regions with human immunoglobulin sequences to create partially- or fully-human antibodies for drug discovery purposes. Examples of such mice include those described in, for example, U.S. Pat Nos. 7,145,056; 7,064,244; 7,041,871; 6,673,986; 6,596,541; 6,570,061; 6,162,963; 6,130,364; 6,091,001; 6,023,010; 5,593,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,661,016; 5,612,205; and 5,591,669.

[00069] The exons that encode the antibody V_H and V_L domains do not exist in the germ-line DNA. Instead, each V_H or V_L exon is generated, respectively, by the recombination of randomly selected V, D, and J genes present in the H chain locus, or of randomly selected V and J genes in the light chain locus. There are multiple V, D, and J genes in the H chain locus as well as multiple V and J genes in each L chain locus, thus allowing for the generation of a vast antibody diversity repertoire per individual when the permutations of H chain VDJ rearrangements are combined with the permutations of L chain VJ gene rearrangements.

[00070] In particularly preferred aspects, the transgenic animals of the invention are as described in co-pending application US Pub. No. 2013/0219535, which is incorporated by reference in its entirety herein. Such transgenic animals have a genome comprising an introduced partially human immunoglobulin region, wherein the endogenous non-human V, D, and J gene coding sequences have been replaced with those of human origin without altering the endogenous noncoding sequences. Preferably, the transgenic cells and animals of the invention have genomes in which part or all of the endogenous immunoglobulin genes are removed.

[00071] In other aspects, the transgenic animals of the invention are avian, preferably chickens.

Use in Antibody Production

[00072] Culturing cells *in vitro* has been the basis of the production of numerous therapeutic biotechnology products, and involves the production of protein products in cells and release into the support medium. The quantity and quality of protein production over time from the cells growing in culture depends on a number of factors, such as, for example, cell density, cell cycle phase, cellular biosynthesis rates of the proteins, condition of the medium used to support cell viability and growth, and the longevity of the cells in culture. (See, for example, Fresney, *Culture of Animal Cells*, Wiley, Blackwell (2010); and *Cell Culture Technology for Pharmaceutical and Cell-Based Therapies,* Ozturk and Ha, Eds., CRC Press, (2006).)

[00073] For certain products, such as monoclonal antibodies, enhancing the presence and protein-expression efficiency of the cells that are actually producing the product is a key aspect of efficient protein production. Capturing antibodies on the surface of ASCs secreting them provides opportunities for discriminating ASCs on the basis of their immunoglobulin specificities, and this in turn provides opportunities for optimizing and enhancing the production of antibodies for various uses.

EXAMPLES

[00074] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent or imply that the experiments below are all of or the only experiments performed. It will be appreciated by persons skilled in

the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

[00075] Efforts have been made to ensure accuracy with respect to terms and numbers used (*e.g.,* vectors, amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees centigrade, and pressure is at or near atmospheric.

Example 1: Expression of a minimal Protein G-containing membrane-bound immunoglobulin-capturing molecule.

[00076] An expression vector encoding a small membrane-bound form of the immunoglobulin-capturing molecule without a stalk is generated by direct DNA synthesis or standard molecular cloning techniques. A diagram of the protein-coding part of this vector (501) is shown in Figure 5A. The expression vector encodes two immunoglobulin-binding domains of streptococcal Protein G (504) [SEQ ID No. 8] that are tethered to the cell surface by means of a membrane-spanning domain derived the human LAG3 (or CD223) protein (506) [SEQ ID No. 17]. A fragment of DNA encoding a short linker consisting of Gly-Ser-Gly-Ser-Gly-Ser sequence (505) [SEQ ID No. 28] is placed between the DNA fragments encoding the Protein G immunoglobulin-binding domains (504) and the transmembrane domain (506) to provide structural flexibility to the expressed protein. Finally, a sequence encoding a signal peptide (leader peptide) (503) is included in the construct to allow for extrusion of the immunoglobulin-capturing molecule into the lumen of the endoplasmic reticulum during its biosynthesis. The signal peptide sequence in this example is derived from an immunoglobulin light chain variable (V_L) gene segment which includes its native intron (503) [SEQ ID Nos. 1-3]. The promoter is indicated at (502). The nucleotide and amino acid sequences of various components comprising the immunoglobulin-capturing molecule in this example are specified in Table 1 and Table 2, respectively.

[00077] The expression vector is transfected into various myeloma, hybridoma or other cell lines using commonly accessible methodology such as electroporation. The transfected cells are then examined for surface expression of the immunoglobulin-

capturing molecule using procedures such as immunofluorescence microscopy, flow cytometry, and/or immunoblotting of the membrane protein fractions. The cells are further analyzed using a subset of these procedures for the capacity of the cell surface immunoglobulin-capturing molecules to retain immunoglobulins produced by the transfected cells or added to them.

[00078] Figure 5B illustrates the expression of this small immunoglobulin-capturing molecule in a plasmacytoma cell line and its ability to retain immunoglobulin molecules on the cell surface. Human RPMI 8226 (ATCC® CCL-155™) cells were transfected with DNA plasmids encoding the immunoglobulin-capturing molecule (501) under control of the *Blimp1* promoter (502). The cells were also co-transfected with a plasmid encoding mouse IgG. Compared to untransfected cells (top, 507), the transfected cells (bottom, 508) exhibit captured immunoglobulins on the cell surface.

[00079] Transgenic animals are then generated to express the membrane-bound immunoglobulin-capturing molecules containing Protein G on the ASCs, and the capacity of the transgene-encoded molecules to capture immunoglobulins on ASCs is determined directly on the ASCs taken from the transgenic mice by standard flow cytometry.

Example 2: Expression of a Protein G-containing membrane-bound immunoglobulin-capturing molecule containing a stalk.

[00080] An expression vector encoding a membrane-bound form of the immunoglobulin-capturing molecule containing a long stalk is generated by direct DNA synthesis or standard molecular cloning techniques. The expression vector encodes three immunoglobulin-binding domains derived from the C-terminal half of streptococcal Protein G [SEQ ID No. 9]. DNA fragments encoding a short linker consisting of Gly-Ser-Gly-Ser-Gly-Ser [SEQ ID No. 28] sequence, a stalk consisting of six immunoglobulin domains derived from human CD22 protein [SEQ ID No. 16], and a transmembrane domain derived from human CD58 [SEQ ID No. 18] are appended to the immunoglobulin-binding domain-encoding DNA fragment of the vector. Finally, a sequence encoding a signal peptide (leader peptide) is placed preceding the entire open-reading frame of the immunoglobulin-capturing molecule to allow for extrusion of the translated protein into the lumen of the endoplasmic reticulum during its biosynthesis. The sequences encoding the signal peptide in this example are derived from an immunoglobulin heavy chain variable (V_H) gene

segment and include its native intron [SEQ ID Nos. 5-7]. The nucleotide and amino acid sequences of components comprising the immunoglobulin-capturing molecule in this example are specified in Table 1 and Table 2, respectively.

[00081] The expression vector is transfected into various myeloma, hybridoma or other cell lines using commonly accessible methodology such as electroporation. The transfected cells are then examined for surface expression of the Protein G molecule using procedures such as immunofluorescence microscopy, flow cytometry and immunoblotting of the cell membrane protein fractions. The cells are further analyzed using a subset of these procedures for the capacity of the cell surface Protein G to capture immunoglobulins produced by the transfected cells or added to them.

[00082] Transgenic animals are then generated to express the membrane-bound immunoglobulin-capturing molecules consisting of Protein G, CD22 and CD58 fusion in the ASCs, and the capacity of the transgene-encoded molecules to capture immunoglobulins on ASCs is determined directly on the ASCs taken from the transgenic mice by standard flow cytometry.

Example 3: Expression of a Protein G-containing immunoglobulin-capturing molecule anchored to the membrane by a GPI post-translational modification

[00083] An expression vector encoding two immunoglobulin-binding domains derived from the streptococcal Protein G is synthesized. Included in this expression vector downstream of the Protein G-encoding sequence are DNA fragments that encode the following: a Gly/Ser-rich linker sequence, a stalk consisting of two immunoglobulin domains of human CD4, and a GPI anchor sequence. Finally, a signal peptide sequence (leader sequence) is included in the construct to allow for extrusion of the translated protein into the lumen of the endoplasmic reticulum during its biosynthesis. The sequences encoding the signal peptide in this example are derived from an immunoglobulin light chain variable (V_L) gene segment and include its native intron. The nucleotide and amino acid sequences of components comprising the immunoglobulin-capturing molecule in this example are specified in Table 1 and Table 2, respectively. The GPI anchor sequences are specified in Table 3.

[00084] The expression vector is transfected into various myeloma, hybridoma or other cell lines using commonly accessible methodology such as electroporation. The transfected cells are then examined for surface expression of the Protein G molecule using procedures such as immunofluorescence microscopy, flow cytometry and

immunoblotting of the cell membrane protein fractions. The cells are further analyzed using a subset of these procedures for the capacity of the cell surface Protein G to capture immunoglobulins produced by the transfected cells or added to them.

[00085] Transgenic animals are then generated to express the GPI-anchored immunoglobulin-capturing molecules in ASCs, and the capacity of the transgene-encoded molecules to capture immunoglobulins on the surface of ASCs is determined directly on the ASCs taken from the transgenic mice by standard flow cytometry.

Example 4: Expression of a membrane-bound scFv derived from an antibody specific for an immunoglobulin constant region.

[00086] An expression vector encoding a scFv specific for the constant domain of an immunoglobulin is generated by standard molecular cloning or direct DNA synthesis. In this example, the single-chain antibody is specific for the constant domain of the mouse kappa light chain, which is present in more than 90% of antibodies found in normal mice. The exon encoding the scFv comprises V_L, linker, and V_H sequences specified at [SEQ ID Nos. 43-48, respectively]. Included in this expression vector downstream of the ScFv-encoding sequence is a contiguous sequence that encodes the Fc part of rat IgG1 consisting of the following: a hinge region, C_H2 domain, and C_H3 domain of the secreted form. The rat IgG1 Fc-encoding sequence is specified at [SEQ ID Nos. 49]. The vector also includes sequences encoding the transmembrane domain of a mouse Major Histocompatibility Complex Class I protein (the mouse K molecule from the b haplotype), specified at [SEQ ID Nos. 50-54].

[00087] The expression vector is transfected into various myeloma, hybridoma and other cell lines using commonly accessible methodology such as electroporation. The transfected cells are examined for surface expression of the single chain antibody molecule using procedures such as immunofluorescence microscopy, flow cytometry and immunoblotting of the cell membrane protein fractions. The cells are further analyzed using a subset of these procedures for the capacity of the cell surface single chain antibody molecule to capture immunoglobulins produced by the transfected cells or added to them.

[00088] Transgenic animals are generated to express the scFv-containing immunoglobulin-capturing molecules on ASCs, and the capacity of the transgene-encoded molecules to capture immunoglobulins on the surface of ASCs is determined by standard flow cytometry directly on the ASCs taken from the mice.

Example 5: Use of transgenic animal expressing immunoglobulin-capturing molecules to isolate ASCs producing monoclonal antibodies against antigen of interest.

[00089] Transgenic mice are generated using a bacterial artificial chromosome vector containing the promoter of human *TNFRSF17* gene, the coding sequence of an immunoglobulin-capturing molecule, for example as in Examples 1-4, an IRES sequence, and GFP. Spleen, lymph nodes, and bone marrow from several transgenic founder lines are harvested, processed, and analyzed for the expression of GFP as well as the immunoglobulin-capturing molecule by standard flow cytometry. GFP-positive cells from the transgenic mice are then pooled, sorted, and verified by enzyme-linked immunospot (ELISPOT) for their ability to secrete immunoglobulins. A transgenic line that stably expresses detectable levels of GFP and the immunoglobulin-capturing molecule is selected for propagation.

[00090] Adult transgenic mice are immunized with an antigen of interest. Spleens as well as the relevant lymph nodes are isolated from the immunized mice, processed, and stained for flow cytometric analyses. Additionally, the isolated cells are subjected to antigen binding during the flow cytometric staining. The antigen is either directly labeled with a fluorophore or with biotin for use with a labeled avidin, streptavidin, or similar system. ASCs are sorted on the basis of GFP-positive staining as well as antigen-positive staining.

[00091] The purified ASCs are then fused to myeloma cells to generate hybridoma cells using established methodologies familiar to those with ordinary skill in the art. In this invention, the provided methods to express the immunoglobulin-capturing molecules also allow for the screening of hybridoma cells based on GFP expression as well as positive staining of antigens captured on the cell surfaces.

[00092] Alternatively, the purified ASCs are individually sorted, and genes encoding their V_H and V_L domains are cloned via RT-PCR or 5' RACE techniques adapted for single cells. The cloned V_H- and V_L- coding sequences are subcloned into an expression vector containing a sequence encoding the desired constant regions of heavy chain and light chain, respectively. The V_H- and V_L-expression vectors are transfected into a HEK-293T or CHO cell lines, and the secreted monoclonal antibodies are further tested for antigen binding and other functions.

Table 1 – exemplary nucleic acid sequences

SEQ ID No.	Description	Corresponding Structure	Sequence
1	Leader Exon1/Intron/ Exon 2/Tags V_L Leader Exon 1	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	ATGGACATCAGGGCTCCTGCTCAGTTTCTTG GCATCTTGTTGCTCTGGTTTCCAG
2	Leader Exon1/Intron/ Exon 2/Tags V_L intron	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	GTAAAATGAACTAAAATGGGAATTTCACTGT AAGTGTTGACAGGCATTTGGGGACTGTGTTC TTTTATCATGCTTACCTTTGTAGATATTCATT ATGTCTCCACTCCTAG
3	Leader Exon1/Intron/ Exon 2/Tags V_L Leader Exon 2	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	GTGCCAGATGTGACATCCAGATG
4	Leader Exon1/Intron/ Exon 2/Tags FLAG+Myc Tags	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	GACTACAAGGATGACGACGACAAGGGCAGC GGCGAACAGAAGCTGATTTCGGAGGAGGAC CTG
5	Leader Exon1/Intron/ Exon 2/Tags V_H Leader Exon 1	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	ATGGGATGGAGCTGTATCATGCTCTTCTTGG CAGCAACAGCTACAG
6	Leader Exon1/Intron/ Exon 2/Tags V_H Intron	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	GTAAGGGGCTCACAGTAGCAGGCTTGAGGTC TGGACATATACATGGGTGACAATGACATCCA CTTTGCCTTTCTCTCCACAG
7	Leader Exon1/Intron/ Exon 2/Tags V_H	Figure 2A, 203 Figure 3A, 303 Figure 5A, 503	GTGTCCACTCCCAGGTCCAACTG
8	Ig-Binding Domain 2-Domain Protein G	Figure 2A, 204 Figure 5A, 504	GGTACCCCAGCCGTGACCACCTACAAGCTCG TCATCAACGGAAAGACGCTCAAGGGCGAAA CCACTACCAAGGCGGTGGATGCCGAAACCGC CGAAAAGGCCTTCAAGCAGTACGCTAACGAC AATGGGGTGGACGGAGTCTGGACGTACGAT GATGCCACCAAGACTTTCACCGTGACCGAAG TGAACACTCCGGCCGTCACCACTTATAAGCT CGTGATCAACGGGAAAACCCTGAAGGGAGA GACTACCACAAAGGCCGTGGATGCTGAGACT GCAGAGAAGGCGTTCAAACAGTACGCCAAC GACAACGGCGTGGACGGCGTCTGGACCTACG ATGACGCCACTAAGACCTTCACTGTGACCGA A
9	Ig-Binding Domain 3-Domain Protein G	Figure 2A, 204 Figure 5A, 504	ATAGATGAAATTTTAGCTGCATTACCTAAGA CTGACACTTACAAATTAATCCTTAATGGTAA AACATTGAAAGGCGAAACAACTACTGAAGC TGTTGATGCTGCTACTGCAGAAAAAGTCTTC AAACAATACGCTAACGACAACGGTGTTGACG

SEQ ID No.	Description	Corresponding Structure	Sequence
			GTGAATGGACTTACGACGATGCGACTAAGAC CTTTACAGTTACTGAAAAACCAGAAGTGATC GATGCGTCTGAATTAACACCAGCCGTGACAA CTTACAAACTTGTTATTAATGGTAAAACATT GAAAGGCGAAACAACTACTGAAGCTGTTGAT GCTGCTACTGCAGAAAAAGTCTTCAAACAAT ACGCTAACGACAACGGTGTTGACGGTGAATG GACTTACGACGATGCGACTAAGACCTTTACA GTTACTGAAAAACCAGAAGTGATCGATGCGT CTGAATTAACACCAGCCGTGACAACTTACAA ACTTGTTATTAATGGTAAAACATTGAAAGGC GAAACAACTACTAAAGCAGTAGACGCAGAA ACTGCAGAAAAAGCCTTCAAACAATACGCTA ACGACAACGGTGTTGATGGTGTTTGGACTTA TGATGATGCGACTAAGACCTTTACGGTAACT GAA
10	Ig-Binding Domain 2-Domain Protein A + 2-Domain Protein G	Figure 2A, 204 Figure 5A, 504	GTGGATAACAAGTTCAACAAGGAACAGCAG AACGCCTTTTACGAGATTCTGCATCTGCCCA ACCTGAATGAGGAACAGCGGAACGCATTCAT TCAGTCTCTGAAGGATGATCCTAGCCAGTCG GCCAACCTCCTGGCTGAAGCAAAGAAGCTGA ACGATGCCCAAGCGCCCAAAGTGGACAACA AGTTTAACAAGGAGCAGCAGAATGCTTTCTA CGAGATCCTGCACCTCCCGAATCTGAACGAG GAGCAGAGAAACGCCTTCATCCAATCACTGA AGGACGACCCGTCACAGTCCGCCAACCTTCT GGCGGAAGCCAAGAAACTGAACGACGCCCA GGCGCCAAAGGTGGACGGATCCGGGTCCGG CAGCGGTACCCCAGCCGTGACCACCTACAAG CTCGTCATCAACGGAAAGACGCTCAAGGGCG AAACCACTACCAAGGCGGTGGATGCCGAAA CCGCCGAAAAGGCCTTCAAGCAGTACGCTAA CGACAATGGGGTGGACGGAGTCTGGACGTA CGATGATGCCACCAAGACTTTCACCGTGACC GAAGTGAACACTCCGGCCGTCACCACTTATA AGCTCGTGATCAACGGGAAAACCCTGAAGG GAGAGACTACCACAAAGGCCGTGGATGCTG AGACTGCAGAGAAGGCGTTCAAACAGTACG CCAACGACAACGGCGTGGACGGCGTCTGGA CCTACGATGACGCCACTAAGACCTTCACTGT GACCGAA
11	Ig-Binding Domain 5-Domain Protein A + 4-Domain Protein G	Figure 2A, 204 Figure 5A, 504	GCCAATGCCGCCCAGCACGACGAGGCTCAGC AGAACGCATTCTACCAGGTGCTGAACATGCC AAACCTCAACGCCGATCAGCGCAATGGTTTC ATTCAGTCCCTGAAGGACGATCCGAGCCAGT CAGCTAACGTGCTCGGGGAGGCCCAAAAGCT GAATGACTCCCAGGCGCCGAAGGCCGACGC CCAGCAAAACAACTTCAACAAGGATCAGCA ATCCGCCTTCTATGAAATCCTGAATATGCCT AACCTGAACGAAGCTCAGCGGAACGGGTTC ATCCAGAGCCTTAAGGACGACCCTAGCCAGT

SEQ ID No.	Description	Corresponding Structure	Sequence
			CCACCAACGTGCTGGGGGAGGCCAAGAAAC TTAACGAATCCCAGGCCCCGAAGGCGGACA ACAACTTTAACAAGGAACAGCAGAACGCCTT TTACGAGATCCTCAACATGCCGAACCTCAAC GAGGAACAGCGCAACGGTTTCATCCAGTCCC TGAAGGACGATCCATCCCAGTCCGCCAACCT GTTGAGCGAGGCGAAGAAGCTGAATGAGTC CCAAGCCCCCAAGGCTGACAACAAGTTCAAT AAGGAACAACAGAATGCCTTCTACGAAATTC TGCACTTGCCCAATCTGAACGAGGAGCAGCG CAACGGCTTCATCCAATCTCTGAAAGACGAC CCGTCGCAGTCGGCCAACTTGCTGGCCGAAG CCAAGAAGCTCAACGACGCTCAGGCCCCTAA GGCCGACAACAAGTTCAACAAAGAGCAACA GAACGCGTTCTACGAGATTCTCCACTTGCCG AACCTGACCGAAGAACAACGGAACGGATTC ATTCAGAGCCTGAAGGATGACCCTTCGGTGT CAAAGGAGATCCTGGCAGAAGCCAAAAAGC TGAACGATGCCCAGGCACCAAAGGAAGAGG ACAACAACAAGCCGGGCGACCCGAGGATCT CCGAAGCCACTGATGGGCTGTCCGATTTTCT GAAGTCACAGACTCCTGCTGAGGACACCGTG AAGTCCATCGAGCTCGCCGAGGCCAAGGTGC TGGCCAACCGGGAGCTGGATAAGTACGGAG TGTCCGACTACTACAAAAACCTGATTAACAA CGCCAAGACTGTGGAAGGAGTGAAGGCATT GATCGATGAAATCCTGGCGGCGCTCCCAAAA ACCGACACCTACAAACTGATTCTCAACGGAA AGACGCTGAAGGGGGAAACTACCACCGAAG CGGTGGACGCCGCCACCGCCGAAAAGGTGTT TAAGCAGTATGCTAACGACAACGGTGTCGAC GGAGAGTGGACCTACGACGACGCCACTAAG ACTTTCACCGTGACCGAGAAGCCCGAGGTCA TCGACGCGAGCGAGCTCACTCCCGCCGTGAC CACCTACAAGCTGGTCATCAATGGAAAGACT CTGAAGGGCGAAACTACTACTGAAGCCGTGG ATGCGGCAACCGCCGAGAAAGTGTTCAAGC AATACGCAAACGATAACGGGGTGGACGGAG AGTGGACCTACGACGATGCCACAAAGACCTT CACCGTCACCGAAAAGCCCGAAGTGATCGAC GCTTCCGAACTGACGCCGGCCGTGACAACTT ACAAGCTCGTCATTAACGGAAAGACCCTTAA GGGCGAAACCACGACCAAGGCAGTGGACGC CGAAACTGCCGAGAAGGCGTTCAAGCAGTA CGCCAACGACAACGGCGTGGACGGAGTGTG GACTTACGATGATGCGACCAAGACGTTCACT GTGACCGAGATGGTCACCGAAGTGCCG
12	Gly/Ser Linker	Figure 2A, 205 Figure 3A, 305 Figure 5A, 505	GGATCCGGCTCCGGATCC
13	Gly/Ser Linker	Figure 2A, 205 Figure 3A, 305	GGAGGCGGAGGCAGCGGAGGCGGTGGCTCG GGAGGCGGAGGCTCG

SEQ ID No.	Description	Corresponding Structure	Sequence
		Figure 5A, 505	
14	Stalk Rat CD2	Figure 2A, 206 Figure 5A, 506	GAGATGGTGTCCAAGCCGATGATCTACTGGG AGTGTTCCAACGCGACTCTGACCTGTGAAGT GCTGGAGGGAACCGACGTGGAACTGAAGCT GTACCAGGGTAAAGAACATCTGCGGTCGTTG CGCCAAAAGACCATGAGCTACCAGTGGACC AACTTGCGGGCGCCTTTCAAGTGCAAAGCCG TCAATAGAGTGTCCCAGGAGAGCGAAATGG AGGTCGTGAACTGCCCCGAAAAGGGACTG
15	Stalk Rat CD4	Figure 2A, 206 Figure 5A, 506	TCAACTTCCATCACCGCCTACAAGAGCGAGG GAGAGAGCGCCGAGTTTTCCTTCCCCCTGAA CCTGGGCGAAGAAAGCCTCCAGGGAGAACT GCGCTGGAAGGCAGAAAAGGCCCCAAGCTC TCAGTCCTGGATCACCTTCAGCCTGAAGAAC CAGAAGGTGTCCGTGCAGAAGTCCACTTCAA ACCCGAAGTTCCAGCTCTCCGAAACCCTCCC TCTGACCCTGCAAATCCCTCAAGTGTCGCTG CAATTCGCGGGGAGCGGAAATCTGACTCTGA CTCTTGACCGGGGCATCTTGTACCAGGAGGT GAACCTGGTGGTCATGAAGGTGACCCAGCCC GATAGCAACACCCTGACCTGTGAAGTGATGG GACCCACGTCCCCGAAGATGCGGCTCATTCT GAAGCAGGAGAACCAGGAGGCTCGGGTGTC CAGACAGGAAAAGGTCATCCAAGTGCAGGC CCCGGAAGCCGGCGTGTGGCAGTGCCTGCTG TCCGAGGGAGAGGAAGTCAAGATGGACTCG AAAATCCAGGTGCTGTCCAAAGGGCTGAACC AGACTATG
16	Stalk Human CD22	Figure 2A, 206 Figure 5A, 506	GAAAGGCCTTTTCCACCTCATATCCAGCTCC CTCCAGAAATTCAAGAGTCCCAGGAAGTCAC TCTGACCTGCTTGCTGAATTTCTCCTGCTATG GGTATCCGATCCAATTGCAGTGGCTCCTAGA GGGGGTTCCAATGAGGCAGGCTGCTGTCACC TCGACCTCCTTGACCATCAAGTCTGTCTTCAC CCGGAGCGAGCTCAAGTTCTCCCCACAGTGG AGTCACCATGGGAAGATTGTGACCTGCCAGC TTCAGGATGCAGATGGGAAGTTCCTCTCCAA TGACACGGTGCAGCTGAACGTGAAGCACACC CCGAAGTTGGAGATCAAGGTCACTCCCAGTG ATGCCATAGTGAGGGAGGGGGACTCTGTGAC CATGACCTGCGAGGTCAGCAGCAGCAACCCG GAGTACACGACGGTATCCTGGCTCAAGGATG GGACCTCGCTGAAGAAGCAGAATACATTCAC GCTAAACCTGCGCGAAGTGACCAAGGACCA GAGTGGGAAGTACTGCTGTCAGGTCTCCAAT GACGTGGGCCCGGGAAGGTCGGAAGAAGTG TTCCTGCAAGTGCAGTATGCCCCGGAACCTT CCACGGTTCAGATCCTCCACTCACCGGCTGT GGAGGGAAGTCAAGTCGAGTTTCTTTGCATG TCACTGGCCAATCCTCTTCCAACAAATTACA CGTGGTACCACAATGGGAAAGAAATGCAGG GAAGGACAGAGGAGAAAGTCCACATCCCAA

SEQ ID No.	Description	Corresponding Structure	Sequence
			AGATCCTCCCCTGGCACGCTGGGACTTATTC CTGTGTGGCAGAAAACATTCTTGGTACTGGA CAGAGGGGCCCGGGAGCTGAGCTGGATGTC CAGTATCCTCCCAAGAAGGTGACCACAGTGA TTCAAAACCCCATGCCGATTCGAGAAGGAGA CACAGTGACCCTTTCCTGTAACTACAATTCC AGTAACCCCAGTGTTACCCGGTATGAATGGA AACCCCATGGCGCCTGGGAGGAGCCATCGCT TGGGGTGCTGAAGATCCAAAACGTTGGCTGG GACAACACAACCATCGCCTGCGCAGCTTGTA ATAGTTGGTGCTCGTGGGCCTCCCCTGTCGC CCTGAATGTCCAGTATGCCCCCCGAGACGTG AGGGTCCGGAAAATCAAGCCCCTTTCCGAGA TTCACTCTGGAAACTCGGTCAGCCTCCAATG TGACTTCTCAAGCAGCCACCCCAAAGAAGTC CAGTTCTTCTGGGAGAAAAATGGCAGGCTTC TGGGGAAAGAAAGCCAGCTGAATTTTGACTC CATCTCCCCAGAAGATGCTGGGAGTTACAGC TGCTGGGTGAACAACTCCATAGGACAGACAG CGTCCAAGGCCTGGACACTTGAAGTGCTGTA TGCACCCAGGAGGCTGCGTGTGTCCATGAGC CCGGGGGACCAAGTGATGGAGGGGAAGAGT GCAACCCTGACCTGTGAGAGCGACGCCAACC CTCCCGTCTCCCACTACACCTGGTTTGACTGG AATAACCAAAGCCTCCCCTACCACAGCCAGA AGCTGAGATTGGAGCCGGTGAAGGTCCAGC ACTCGGGTGCCTACTGGTGCCAGGGGACCAA CAGTGTGGGCAAGGGCCGTTCGCCTCTCAGC ACCCTCACCGTCTACTATAGCCCGGAGACC
17	Transmembrane Domain Human LAG3	Figure 2A, 207 Figure 5A, 507	GCGCCTGGAGCGCTGCCGGCCGGTCATCTGT TGTTGTTCCTGACCCTGGGGGTGCTGTCACTG CTGCTGCTCGTGACCGGGGCATTCGGTTTCC ACCTGTGGAGAAGGCAGTGGCGGTAG
18	Transmembrane Domain Human CD58	Figure 2A, 207 Figure 5A, 507	CATTCCCGGCACCGCTACGCGCTGATTCCGA TTCCTCTGGCCGTGATCACCACCTGTATCGTG CTCTACATGAACGGTATCCTGAAATGCGACA GAAAGCCCGACAGGACTAACAGCAATTAG
19	Transmembrane Domain Rat CD2	Figure 2A, 207 Figure 5A, 507	CCGCTGTACCTGATCGTGGGGGTGTCAGCCG GCGGTCTGCTGCTCGTGTTCTTCGGGGCACT GTTCATCTTCTGCATTTGCAAGAGGAAGAAG CGGTAG
20	Transmembrane Domain Human CD7	Figure 2A, 207 Figure 5A, 507	CCACCCCGGGCGTCCGCACTGCCGGCGCCCC CTACCGGAAGCGCGCTGCCCGATCCGCAAAC CGCCAGCGCCCTGCCTGACCCGCCCGCGGCT AGCGCCTTGCCTGCCGCACTGGCCGTGATTT CATTCCTGCTGGGTCTGGGGCTCGGGGTGGC CTGCGTGTTGGCACGGACTCAGATCAAGAAG CTGTGCTCCTGGAGAGACAAAAACTCCGCCG CCTGTGTGGTGTACGAGGACATGTCACACTC GAGGTGCAATACCCTGTCCTCGCCGAACCAG TACCAGTAG

Table 2 exemplary peptide sequences

SEQ ID No.	Description	Corresponding Structure	Sequence
21	Leader Exon1/Intron/ Exon 2/Tags V_L Leader Exon		MGWSCIMLFLAATATGVHSQVQL
22	Leader Exon1/Intron/ Exon 2/Tags FLAG+Myc Tags		DYKDDDDKGSGEQKLISEEDL
23	Leader Exon1/Intron/ Exon 2/Tags V_H Leader Exon		MDIRAPAQFLGILLLWFPGARCDIQM
24	Ig-Binding Domain 2-Domain Protein G	Figure 2B, 208	GTPAVTTYKLVINGKTLKGETTTKAVDAETAE KAFKQYANDNGVDGVWTYDDATKTFTVTEV NTPAVTTYKLVINGKTLKGETTTKAVDAETAE KAFKQYANDNGVDGVWTYDDATKTFTVTE
25	Ig-Binding Domain 3-Domain Protein G	Figure 2B, 208	IDEILAALPKTDTYKLILNGKTLKGETTTEAVD AATAEKVFKQYANDNGVDGEWTYDDATKTF TVTEKPEVIDASELTPAVTTYKLVINGKTLKGE TTTEAVDAATAEKVFKQYANDNGVDGEWTY DDATKTFTVTEKPEVIDASELTPAVTTYKLVIN GKTLKGETTTKAVDAETAEKAFKQYANDNGV DGVWTYDDATKTFTVTE
26	Ig-Binding Domain 2-Domain Protein A + 2-Domain Protein G	Figure 2B, 208	VDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQS LKDDPSQSANLLAEAKKLNDAQAPKVDNKFN KEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPS QSANLLAEAKKLNDAQAPKVDGSGSGSGTPA VTTYKLVINGKTLKGETTTKAVDAETAEKAFK QYANDNGVDGVWTYDDATKTFTVTEVNTPA VTTYKLVINGKTLKGETTTKAVDAETAEKAFK QYANDNGVDGVWTYDDATKTFTVTE
27	Ig-Binding Domain 5-Domain Protein A + 4-Domain Protein G	Figure 2B, 208	ANAAQHDEAQQNAFYQVLNMPNLNADQRNG FIQSLKDDPSQSANVLGEAQKLNDSQAPKADA QQNNFNKDQQSAFYEILNMPNLNEAQRNGFIQ SLKDDPSQSTNVLGEAKKLNESQAPKADNNFN KEQQNAFYEILNMPNLNEEQRNGFIQSLKDDPS QSANLLSEAKKLNESQAPKADNKFNKEQQNAF YEILHLPNLNEEQRNGFIQSLKDDPSQSANLLA EAKKLNDAQAPKADNKFNKEQQNAFYEILHLP NLTEEQRNGFIQSLKDDPSVSKEILAEAKKLND AQAPKEEDNNKPGDPRISEATDGLSDFLKSQTP AEDTVKSIELAEAKVLANRELDKYGVSDYYKN LINNAKTVEGVKALIDEILAALPKTDTYKLILN GKTLKGETTTEAVDAATAEKVFKQYANDNGV DGEWTYDDATKTFTVTEKPEVIDASELTPAVT TYKLVINGKTLKGETTTEAVDAATAEKVFKQY ANDNGVDGEWTYDDATKTFTVTEKPEVIDASE LTPAVTTYKLVINGKTLKGETTTKAVDAETAE KAFKQYANDNGVDGVWTYDDATKTFTVTEM

SEQ ID No.	Description	Corresponding Structure	Sequence
			VTEVP
28	Gly/Ser Linker	Figure 2B, 209	GSGSGS
29	Gly/Ser Linker	Figure 2B, 209	GGGGSGGGGSGGGGS
30	Stalk Rat CD2	Figure 2B, 210	EMVSKPMIYWECSNATLTCEVLEGTDVELKLY QGKEHLRSLRQKTMSYQWTNLRAPFKCKAVN RVSQESEMEVVNCPEKGL
31	Stalk Rat CD4	Figure 2B, 210	STSITAYKSEGESAEFSFPLNLGEESLQGELRW KAEKAPSSQSWITFSLKNQKVSVQKSTSNPKFQ LSETLPLTLQIPQVSLQFAGSGNLTLTLDRGILY QEVNLVVMKVTQPDSNTLTCEVMGPTSPKMR LILKQENQEARVSRQEKVIQVQAPEAGVWQCL LSEGEEVKMDSKIQVLSKGLNQTM
32	Stalk Human CD22	Figure 2B, 210	MKVTQPDSNTLTCEVMGPTSPKMRLILKQENQ EARVSRQEKVIQVQAPEAGVWQCLLSEGEEVK MDSKIQVLSKGLNQTM
33	Transmembrane Domain Human LAG3	Figure 2B, 211	APGALPAGHLLLFLTLGVLSLLLLVTGAFGFHL WRRQWR
34	Transmembrane Domain Human CD58	Figure 2B, 211	HSRHRYALIPIPLAVITTCIVLYMNGILKCDRKP DRTNSN
35	Transmembrane Domain Rat CD2	Figure 2B, 211	PLYLIVGVSAGGLLLVFFGALFIFCICKRKKR
36	Transmembrane Domain Human CD7	Figure 2B, 211	PPRASALPAPPTGSALPDPQTASALPDPPAASA LPAALAVISFLLGLGLGVACVLARTQIKKLCSW RDKNSAACVVYEDMSHSRCNTLSSPNQYQ

Table 3—GPI anchor sequences

SEQ ID No.	Description	Sequence
37	Human CD59	GAATTCCTTGAAAATGGTGGGACATCCTTATCAGAGAAAACAG TTCTTCTGCTGGTGACTCCATTTCTGGCAGCAGCCTGGAGCCTTC ATCCC
38	Human CD59	EFLENGGTSLSEKTVLLLVTPFLAAAWSLHP
39	Human CD24	ACCAATGCCACAACAAAGGCAGCAGGGGGAGCACTCCAGTCAA CAGCAAGTTTGTTTGTCGTGTCACTGAGTCTCTTGCATCTTTATT CA
40	Human CD24	TNATTKAAGGALQSTASLFVVSLSLLHLYS
41	Human CNTN1 (Contactin 1)	GTCTCCCAGGTGAAAATTTCAGGAGCCCCTACCCTCTCCCCATC CCTCCTGGGTTTGCTGCTGCCCGCCTTTGGCATTCTCGTGTATCT GGAGTTC
42	Human CNTN1 (Contactin 1)	VSQVKISGAPTLSPSLLGLLLPAFGILVYLEF

Table 4—Example 4 sequences

SEQ ID No.	Description	Sequence
43	V_L Leader exon 1	ATGGAATCACAGACCCAGGTCCTCATGTTTCTTCTGCTCTGGGT ATCTG
44	V_L intron	GTAAGAAATTTAAAGTATTAAAACCTTTTCAAAGTTTCATCTTT GTGGTAAGAAATTTGCAATATGTGCCAGTGTGTAATATTTCTTA CATAATAAATTTGTGACAGTATGATAAGGACATTTAAATGAAA AATTTCGACTGTTGTTATAATCTATGTCTGTGTATCTATGAATTT TCACTGCCTATTAATTATTACAG
45	V_L exon 2 end of VL leader sequence	GTGCCTGTGCA
46	V_L exon 2	GACATTCAGATGACCCAGTCTCCATCCTCCATGTCTGTGTCTCT GGGAGACACAGTCACTATTACTTGCCGGGCAAGTCAGGACGTT GGGATTTATGTAAACTGGTTCCAGCAGAAACCAGGGAAATCTC CTAGGCGTATGATTTATCGTGCAACGAACTTGGCAGATGGGGTC CCATCAAGGTTCAGCGGCAGTAGGTCTGGATCAGATTATTCTCT CACCATCAGCAGCCTGGAGTCTGAAGATGTGGCAGACTATCAC TGTCTACAGTATGATGAGTATCCATTCACGTTCGGATCCGGGAC GAAGTTGGAAATAAAACGG
47	V_L exon 2 linker	GGAGGCGGAGGCAGCGGAGGCGGTGGCTCGGGAGGCGGAGGC TCG
48	V_H exon 2	CAGGTACAGCTGAAAGAGTCAGGACCTGGTCTGGTGCAGCCCT CACAGACCCTGTCTCTCACCTGCACTGTCTCTGGACTCTCATTA ATCAGTTATGGTGTAAGTTGGGCTCGCCAGCCTCCAGGGAAGG GTCTGGAGTGGATTGCAGCAATATCAAGTGGTGGAAGCACATA TTATAATTCAGTTCTCACATCTCGACTGAGCATCAGCAGGGACA CCTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAACT GAAGACACAGCCATTTACTTCTGTACCAGAGAACTCTGGGACTA CTATGATTACTGGGGCCAAGGAGTCATGGTCACAGTCTCCTCA
49	Exon 2-Rat	GCTGAAACAACAGCCCCCAGAAACCCGGGAGGTGATTGCAAGC

SEQ ID No.	Description	Sequence
	IgG1 Fc	CTTGTATATGTACAGGCTCAGAAGTATCATCTGTCTTCATCTTCC CCCCAAAGCCCAAAGATGTGCTCACCATCACTCTGACTCCTAAG GTCACGTGTGTTGTGGTAGACATTAGCCAGGACGATCCCGAGGT CCATTTCAGCTGGTTTGTAGATGACGTGGAAGTCCACACAGCTC AGACTCGACCACCAGAGGAGCAGTTCAACAGCACTTTCCGCTC AGTCAGTGAACTCCCCATCCTGCACCAGGACTGGCTCAATGGCA GGACGTTCAGATGCAAGGTCACCAGTGCAGCTTTCCCATCCCCC ATCGAGAAAACCATCTCCAAACCCGAAGGCAGAACACAAGTTC CGCATGTATACACCATGTCACCTACCAAGGAAGAGATGACCCA GAATGAAGTCAGTATCACCTGCATGGTAAAAGGCTTCTATCCCC CAGACATTTATGTGGAGTGGCAGATGAACGGGCAGCCACAGGA AAACTACAAGAACACTCCACCTACGATGGACACAGATGGGAGT TACTTCCTCTACAGCAAGCTCAATGTGAAGAAGGAAAAATGGC AGCAGGGAAACACGTTCACGTGTTCTGTGCTGCATGAAGGCCT GCACAACCACCATACTGAGAAGAGTCTCTCCCACTCCCCCGGT
50	Exon 2 part of mouse MHC I ($H2K^b$) transmembrane domain	AAAGAGCCTCCTCCATCCACTGTCTCCAACATGGCGACCGTTGC TGTTCTGGTTGTCCTTGGAGCTGCAATAGTCACTGGAGCTGTGG TGGCTTTTGTGATGAAGATGAGAAGGAGAAACACAG
51	Intron	GTAGGAAAGGGCAGAGTCTGAGTTTTCTCTCAGCCTCCTTTAGA GTGTGCTCTGCTCATCAATGGGGAACACAGGCACACCCCACATT GCTACTGTCTCTAACTGGGTCTGCTGTCAGTTCTGGGAACTTCCT AGTGTCAAGATCTTCCTGGAACTCTCACAGCTTTTCTTCTCACA G
52	Exon 3-part of mouse MHC I ($H2K^b$) transmembrane domain	GTGGAAAAGGAGGGGACTATGCTCTGGCTCCAG
53	Intron	GTTAGTGTGGGGACAGAGTTGTCCTGGGGACATTGGAGTGAAG TTGGAGATGATGGGAGCTCTGGGAATCCATAATAGCTCCTCCAG AGAAATCTTCTAGGTGCCTGAGTTGTGCCATGAAATGAATATGT ACATGTACATATGCATATACATTTGTTTTGTTTTACCCTAG
54	Exon 4 – end of mouse MHC I ($H2K^b$) transmembrane domain	GCTCCCAGACCTCTGATCTGTCTCTCCCAGATTGTAAAGGTGAC ACTCTAGGGTCTGATTGGGGAGGGGCAATGTGGACATGA
55	V_L leader	MESQTQVLMFLLLWVSGACA
56	V_L	DIQMTQSPSSMSVSLGDTVTITCRASQDVGIYVNWFQQKPGKSPRR MIYRATNLADGVPSRFSGSRSGSDYSLTISSLESEDVADYHCLQYD EYPFTFGSGTKLEIKR
29	Linker	GGGGSGGGGSGGGGS
57	V_H	QVQLKESGPGLVQPSQTLSLTCTVSGLSLISYGVSWARQPPGKGLE WIAAISSGGSTYYNSVLTSRLSISRDTSKSQVFLKMNSLQTEDTAIY FCTRELWDYYDYWGQGVMVTVSS
58	Rat IgG1 Fc	AETTAPRNPGGDCKPCICTGSEVSSVFIFPPKPKDVLTITLTPKVTCV VVDISQDDPEVHFSWFVDDVEVHTAQTRPPEEQFNSTFRSVSELPIL HQDWLNGRTFRCKVTSAAFPSPIEKTISKPEGRTQVPHVYTMSPTK EEMTQNEVSITCMVKGFYPPDIYVEWQMNGQPQENYKNTPPTMD

SEQ ID No.	Description	Sequence
		TDGSYFLYSKLNVKKEKWQQGNTFTCSVLHEGLHNHHTEKSLSHS PG
59	Mouse MHC I ($H2K^b$) transmembrane domain	KEPPPSTVSNMATVAVLVVLGAAIVTGAVVAFVMKMRRRNTGGK GGDYALAPGSQTSDLSLPDCKGDTLGSDWGGAMWT

[00093] The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, *i.e.*, any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims. In the claims that follow, unless the term "means" is used, none of the features or elements recited therein should be construed as means-plus-function limitations pursuant to 35 U.S.C. §112, ¶6.

2017213633 30 Jun 2023

We Claim:

1. A method for generating an antibody-secreting cell capable of expressing a membrane-bound immunoglobulin-capturing molecule that can bind, retain, and display endogenously produced immunoglobulin molecules at its cell surface, comprising the step of:

introducing into the antibody-secreting cell, or the progenitor of an antibody-secreting cell, a nucleic acid vector,

wherein the nucleic acid vector comprises a promoter operably connected to a nucleic acid sequence;

wherein the nucleic acid sequence encodes an immunoglobulin-capturing molecule comprising an immunoglobulin-binding portion and a cell surface tether portion;

wherein the cell surface tether portion comprises a transmembrane peptide or a C-terminal peptide sequence that can be post-translationally modified to tether the immunoglobulin-binding portion to the cell surface of the antibody-secreting cell; and

wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin.

2. The method of claim 1, wherein the bacterial protein is Protein A or Protein G.
3. Part of or whole immunoglobulin molecules derived from the antibody-secreting cell generated by the method of claim1 or 2.
4. The method of claim 1, wherein the antibody- secreting cell is a hybridoma cell or a cell of B lymphocyte lineage.
5. Part of or whole immunoglobulin molecules derived from the cell generated by the method of claim 4.
6. The method of claim 1, wherein the promoter is a constitutive promoter.
7. The method of claim 6, wherein the promoter expresses the immunoglobulin-capturing molecule preferentially in antibody-secreting cells with minimal expression during B cell development prior to antigen encounter.

2017213633 30 Jun 2023

8. The method of claim 7, wherein the promoter is selected from *B Lymphocyte-Induced Maturation Protein 1, Syndecan 1, Tumor Necrosis Factor Receptor Superfamily Member 17,* or *Fucosyltransferase I* genes.

9. The method of claim 1, wherein the promoter is an inducible promoter.

10. The method of claim 9, wherein the inducible promoter is a tetracycline-responsive promoter or a tamoxifen-responsive promoter.

11. The method of any one of claims 1 to 10, wherein the transmembrane peptide is derived from human Lymphocyte Activation Gene 3, human CD58, rat CD2, or human CD7.

12. The method of any one of claims 1 to 11, wherein the C-terminal peptide sequence mediates glycosylphosphatidylinositol linkage to the plasma membrane.

13. The method of any one of claims 1 to 12, wherein the nucleic acid vector further comprises a nucleic acid sequence coding for a stalk structure.

14. The method of any one of claims 1 to 13, wherein the nucleic acid vector further comprises a nucleic acid sequence coding for a reporter peptide.

15. The method of claim 14, wherein the reporter peptide is a fluorescent peptide.

16. The method of any one of claims 1 to 15, wherein the nucleic acid vector further comprises an IRES sequence or a picornavirus 2A ribosomal skip sequence.

17. The method of any one of claims 1 to 16, wherein the nucleic acid vector further comprises a nucleic acid sequence coding for a signal peptide.

18. The method of claim 17, wherein the nucleic acid vector further comprises nucleic acid sequences coding for a stalk structure and a reporter peptide linked to an IRES sequence or picornavirus 2A ribosomal skip sequence.

19. An antibody-secreting cell produced by any one of claims 1 to 18.

20. Part of or whole immunoglobulin molecules derived from the antibody-secreting cell of claim 19.

21. The method of any one of claims 1 to 20, wherein the antibody-secreting cell is used for large-scale production of antibodies.

22. A genetically modified rodent comprising antibody-secreting cells comprising an exogenous nucleic acid sequence comprising:

a promoter, that is expressed in the antibody-secreting cells; and

a nucleic acid sequence encoding an immunoglobulin-capturing molecule comprising a cell surface tether portion and an immunoglobulin-binding portion,

wherein the promoter is operably linked to the nucleic acid sequence encoding the immunoglobulin-capturing molecule;

wherein the cell surface tether portion comprises a transmembrane peptide or a C-terminal peptide sequence that can be post-translationally modified to tether the immunoglobulin-binding portion to the cell surface of the antibody-secreting cell;

wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin; and

wherein the antibody secreting cells of the genetically modified rodent are capable of producing immunoglobulin-capturing molecules that can bind, retain, and display endogenously produced immunoglobulin molecules at a cell surface of the antibody- secreting cells.

23. The genetically modified rodent of claim 22, wherein the antibody-secreting cells constitutively express the immunoglobulin-capturing molecule.

24. The genetically modified rodent of claim 22 or 23, wherein the antibody-secreting cells can be induced to express the immunoglobulin-capturing molecule *in vivo*, *in vitro*, or *ex vivo*.

25. The genetically modified rodent of any one of claims 22 to 24, wherein the rodent is a mouse or a rat.

26. A vector for expressing a membrane-bound immunoglobulin-capturing molecule that can bind, retain, and display immunoglobulin molecules at a cell surface of an antibody-secreting cell, comprising a promoter operably connected to a nucleic acid sequence,

wherein the nucleic acid sequence encodes an immunoglobulin-capturing molecule comprising an immunoglobulin-binding portion and a cell surface tether portion;

wherein the cell surface tether portion comprises a transmembrane peptide or a C-terminal peptide sequence that can be post-translationally modified to tether the immunoglobulin-binding portion to the cell surface of the antibody-secreting cell; and

2017213633 30 Jun 2023

wherein the immunoglobulin-binding portion is selected from (a) one or more bacterial proteins that naturally have affinity for the constant region of a heavy or light chain of an immunoglobulin, (b) one or more variable domains of an immunoglobulin that has affinity for any part of another immunoglobulin, or (c) a single chain variable fragment against a heavy or light chain constant region of an immunoglobulin.

27. The vector of claim 26, further comprising nucleic acid sequences coding for a signal peptide, a stalk structure, and a reporter peptide linked to an IRES sequence or picornavirus 2A ribosomal skip sequence.



FIG. 1C



FIG. 1B



FIG. 1A



FIG. 2A



FIG. 2B


303
304
305
306
307
308
309
301

FIG. 3A


302
311
311
312
312
310
310
313
314
315
316

FIG. 3B



FIG. 4C



FIG. 4B



FIG. 4A


502
503
504
505
506
501

FIG. 5A

FIG. 5B


1000
800
600
400
200
0
10^0
10^1
10^2
10^3
CONTROL
507
TRANSFECTED
508
FSC
CAPTURED ANTIBODY

SEQUENCE LISTING

<110> Trianni, Inc.

<120> Enhanced Production of Immunglobulins

<130> TRIA008US

<150> 62/291,217
<151> 2016-02-04

<160> 59

<170> PatentIn version 3.5

<210> 1
<211> 55
<212> DNA
<213> Homo sapiens

<400> 1
atggacatca gggctcctgc tcagtttctt ggcatcttgt tgctctggtt tccag 55

<210> 2
<211> 110
<212> DNA
<213> Homo sapiens

<400> 2
gtaaaatgaa ctaaaatggg aatttcactg taagtgttga caggcatttg gggactgtgt 60

tcttttatca tgcttacctt tgtagatatt cattatgtct ccactcctag 110

<210> 3
<211> 23
<212> DNA
<213> Homo sapiens

<400> 3
gtgccagatg tgacatccag atg 23

<210> 4
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Leader Exon1/Intron/Exon 2/TagsFLAG+Myc Tags

<400> 4
gactacaagg atgacgacga caagggcagc ggcgaacaga agctgatttc ggaggaggac 60

ctg 63

<210> 5
<211> 46
<212> DNA
<213> Homo sapiens

<400> 5
atgggatgga gctgtatcat gctcttcttg gcagcaacag ctacag 46

<210> 6

<211> 82
<212> DNA
<213> Homo sapiens

<400> 6
gtaaggggct cacagtagca ggcttgaggt ctggacatat acatgggtga caatgacatc 60

cactttgcct ttctctccac ag 82

<210> 7
<211> 23
<212> DNA
<213> Homo sapiens

<400> 7
gtgtccactc ccaggtccaa ctg 23

<210> 8
<211> 369
<212> DNA
<213> Escherichia coli

<400> 8
ggtaccccag ccgtgaccac ctacaagctc gtcatcaacg gaaagacgct caagggcgaa 60

accactacca aggcggtgga tgccgaaacc gccgaaaagg ccttcaagca gtacgctaac 120

gacaatgggg tggacggagt ctggacgtac gatgatgcca ccaagacttt caccgtgacc 180

gaagtgaaca ctccggccgt caccacttat aagctcgtga tcaacgggaa aaccctgaag 240

ggagagacta ccacaaaggc cgtggatgct gagactgcag agaaggcgtt caaacagtac 300

gccaacgaca acggcgtgga cggcgtctgg acctacgatg acgccactaa gaccttcact 360

gtgaccgaa 369

<210> 9
<211> 621
<212> DNA
<213> Escherichia coli

<400> 9
atagatgaaa ttttagctgc attacctaag actgacactt acaaattaat ccttaatggt 60

aaaacattga aaggcgaaac aactactgaa gctgttgatg ctgctactgc agaaaaagtc 120

ttcaaacaat acgctaacga caacggtgtt gacggtgaat ggacttacga cgatgcgact 180

aagaccttta cagttactga aaaaccagaa gtgatcgatg cgtctgaatt aacaccagcc 240

gtgacaactt acaaacttgt tattaatggt aaaacattga aaggcgaaac aactactgaa 300

gctgttgatg ctgctactgc agaaaaagtc ttcaaacaat acgctaacga caacggtgtt 360

gacggtgaat ggacttacga cgatgcgact aagaccttta cagttactga aaaaccagaa 420

gtgatcgatg cgtctgaatt aacaccagcc gtgacaactt acaaacttgt tattaatggt 480

aaaacattga aaggcgaaac aactactaaa gcagtagacg cagaaactgc agaaaaagcc 540

ttcaaacaat acgctaacga caacggtgtt gatggtgttt ggacttatga tgatgcgact 600

aagaccttta cggtaactga a 621

<210> 10
<211> 741
<212> DNA
<213> Escherichia coli

<400> 10
gtggataaca agttcaacaa ggaacagcag aacgcctttt acgagattct gcatctgccc 60

aacctgaatg aggaacagcg gaacgcattc attcagtctc tgaaggatga tcctagccag 120

tcggccaacc tcctggctga agcaaagaag ctgaacgatg cccaagcgcc caaagtggac 180

aacaagttta acaaggagca gcagaatgct ttctacgaga tcctgcacct cccgaatctg 240

aacgaggagc agagaaacgc cttcatccaa tcactgaagg acgacccgtc acagtccgcc 300

aaccttctgg cggaagccaa gaaactgaac gacgcccagg cgccaaaggt ggacggatcc 360

gggtccggca gcggtacccc agccgtgacc acctacaagc tcgtcatcaa cggaaagacg 420

ctcaagggcg aaaccactac caaggcggtg gatgccgaaa ccgccgaaaa ggccttcaag 480

cagtacgcta acgacaatgg ggtggacgga gtctggacgt acgatgatgc caccaagact 540

ttcaccgtga ccgaagtgaa cactccggcc gtcaccactt ataagctcgt gatcaacggg 600

aaaaccctga agggagagac taccacaaag gccgtggatg ctgagactgc agagaaggcg 660

ttcaaacagt acgccaacga caacggcgtg gacggcgtct ggacctacga tgacgccact 720

aagaccttca ctgtgaccga a 741

<210> 11
<211> 1681
<212> DNA
<213> Escherichia coli

<400> 11
aaacctcaac gccgatcagc gcaatggttt cattcagtcc ctgaaggacg atccgagcca 60

gtcagctaac gtgctcgggg aggcccaaaa gctgaatgac tcccaggcgc cgaaggccga 120

cgcccagcaa aacaacttca acaaggatca gcaatccgcc ttctatgaaa tcctgaatat 180

gcctaacctg aacgaagctc agcggaacgg gttcatccag agccttaagg acgaccctag 240

ccagtccacc aacgtgctgg gggaggccaa gaaacttaac gaatcccagg ccccgaaggc 300

ggacaacaac tttaacaagg aacagcagaa cgccttttac gagatcctca acatgccgaa 360

cctcaacgag gaacagcgca acggtttcat ccagtccctg aaggacgatc catcccagtc 420

cgccaacctg ttgagcgagg cgaagaagct gaatgagtcc caagccccca aggctgacaa 480

caagttcaat aaggaacaac agaatgcctt ctacgaaatt ctgcacttgc ccaatctgaa 540

cgaggagcag cgcaacggct tcatccaatc tctgaaagac gacccgtcgc agtcggccaa 600

cttgctggcc gaagccaaga agctcaacga cgctcaggcc cctaaggccg acaacaagtt 660

caacaaagag caacagaacg cgttctacga gattctccac ttgccgaacc tgaccgaaga 720

acaacggaac ggattcattc agagcctgaa ggatgaccct tcggtgtcaa aggagatcct 780

ggcagaagcc aaaaagctga acgatgccca ggcaccaaag gaagaggaca acaacaagcc 840

gggcgacccg aggatctccg aagccactga tgggctgtcc gattttctga agtcacagac 900

tcctgctgag gacaccgtga agtccatcga gctcgccgag gccaaggtgc tggccaaccg 960

ggagctggat aagtacggag tgtccgacta ctacaaaaac ctgattaaca acgccaagac 1020

tgtggaagga gtgaaggcat tgatcgatga aatcctggcg gcgctcccaa aaaccgacac 1080

ctacaaactg attctcaacg gaaagacgct gaaggggaa actaccaccg aagcggtgga 1140

cgccgccacc gccgaaaagg tgtttaagca gtatgctaac gacaacggtg tcgacggaga 1200

gtggacctac gacgacgcca ctaagacttt caccgtgacc gagaagcccg aggtcatcga 1260

cgcgagcgag ctcactcccg ccgtgaccac ctacaagctg gtcatcaatg gaaagactct 1320

gaagggcgaa actactactg aagccgtgga tgcggcaacc gccgagaaag tgttcaagca 1380

atacgcaaac gataacgggg tggacggaga gtggacctac gacgatgcca caaagacctt 1440

caccgtcacc gaaaagcccg aagtgatcga cgcttccgaa ctgacgccgg ccgtgacaac 1500

ttacaagctc gtcattaacg gaaagaccct taagggcgaa accacgacca aggcagtgga 1560

cgccgaaact gccgagaagg cgttcaagca gtacgccaac gacaacggcg tggacggagt 1620

gtggacttac gatgatgcga ccaagacgtt cactgtgacc gagatggtca ccgaagtgcc 1680

g 1681

<210> 12
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Gly/Ser linker

<400> 12
ggatccggct ccggatcc 18

<210> 13
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Gly/Ser linker

<400> 13
ggaggcggag gcagcggagg cggtggctcg ggaggcggag gctcg 45

<210> 14
<211> 243
<212> DNA
<213> Rattus rattus

<400> 14
gagatggtgt ccaagccgat gatctactgg gagtgttcca acgcgactct gacctgtgaa 60

gtgctggagg gaaccgacgt ggaactgaag ctgtaccagg gtaaagaaca tctgcggtcg 120

ttgcgccaaa agaccatgag ctaccagtgg accaacttgc gggcgccttt caagtgcaaa 180

gccgtcaata gagtgtccca ggagagcgaa atggaggtcg tgaactgccc cgaaaaggga 240

ctg 243

<210> 15
<211> 561
<212> DNA
<213> Rattus rattus

<400> 15
tcaacttcca tcaccgccta caagagcgag ggagagagcg ccgagtttc cttccccctg 60

aacctgggcg aagaaagcct ccagggagaa ctgcgctgga aggcagaaaa ggccccaagc 120

tctcagtcct ggatcacctt cagcctgaag aaccagaagg tgtccgtgca gaagtccact 180

tcaaacccga agttccagct ctccgaaacc ctccctctga ccctgcaaat ccctcaagtg 240

tcgctgcaat tcgcggggag cggaaatctg actctgactc ttgaccgggg catcttgtac 300

caggaggtga acctggtggt catgaaggtg acccagcccg atagcaacac cctgacctgt 360

gaagtgatgg gacccacgtc cccgaagatg cggctcattc tgaagcagga gaaccaggag 420

gctcgggtgt ccagacagga aaaggtcatc caagtgcagg ccccggaagc cggcgtgtgg 480

cagtgcctgc tgtccgaggg agaggaagtc aagatggact cgaaaatcca ggtgctgtcc 540

aaagggctga accagactat g 561

<210> 16
<211> 1638
<212> DNA
<213> Homo sapiens

<400> 16
gaaaggcctt ttccacctca tatccagctc cctccagaaa ttcaagagtc ccaggaagtc 60

actctgacct gcttgctgaa tttctcctgc tatgggtatc cgatccaatt gcagtggctc 120

ctagaggggg ttccaatgag gcaggctgct gtcacctcga cctccttgac catcaagtct 180

gtcttcaccc ggagcgagct caagttctcc ccacagtgga gtcaccatgg gaagattgtg 240

acctgccagc ttcaggatgc agatgggaag ttcctctcca atgacacggt gcagctgaac 300

gtgaagcaca ccccgaagtt ggagatcaag gtcactccca gtgatgccat agtgagggag 360

ggggactctg tgaccatgac ctgcgaggtc agcagcagca acccggagta cacgacggta 420

tcctggctca aggatgggac ctcgctgaag aagcagaata cattcacgct aaacctgcgc 480

gaagtgacca aggaccagag tgggaagtac tgctgtcagg tctccaatga cgtgggcccg 540

ggaaggtcgg aagaagtgtt cctgcaagtg cagtatgccc cggaaccttc cacggttcag 600

atcctccact caccggctgt ggagggaagt caagtcgagt ttctttgcat gtcactggcc 660

aatcctcttc caacaaatta cacgtggtac cacaatggga aagaaatgca gggaaggaca 720

gaggagaaag tccacatccc aaagatcctc ccctggcacg ctgggactta ttcctgtgtg 780

gcagaaaaca ttcttggtac tggacagagg ggcccgggag ctgagctgga tgtccagtat 840

cctcccaaga aggtgaccac agtgattcaa aaccccatgc cgattcgaga aggagacaca 900

gtgacccttt cctgtaacta caattccagt aaccccagtg ttacccggta tgaatggaaa 960

ccccatggcg cctgggagga gccatcgctt ggggtgctga agatccaaaa cgttggctgg 1020

gacaacacaa ccatcgcctg cgcagcttgt aatagttggt gctcgtgggc ctcccctgtc 1080

gccctgaatg tccagtatgc cccccgagac gtgagggtcc ggaaaatcaa gccccttcc 1140

gagattcact ctggaaactc ggtcagcctc caatgtgact tctcaagcag ccaccccaaa 1200

gaagtccagt tcttctggga gaaaaatggc aggcttctgg ggaaagaaag ccagctgaat 1260

tttgactcca tctccccaga agatgctggg agttacagct gctgggtgaa caactccata 1320

ggacagacag cgtccaaggc ctggacactt gaagtgctgt atgcacccag gaggctgcgt 1380

gtgtccatga gcccggggga ccaagtgatg gaggggaaga gtgcaaccct gacctgtgag 1440

agcgacgcca accctcccgt ctcccactac acctggtttg actggaataa ccaaagcctc 1500

ccctaccaca gccagaagct gagattggag ccggtgaagg tccagcactc gggtgcctac 1560

tggtgccagg ggaccaacag tgtgggcaag ggccgttcgc ctctcagcac cctcaccgtc 1620

tactatagcc cggagacc 1638

<210> 17
<211> 120
<212> DNA
<213> Homo sapiens

<400> 17
gcgcctggag cgctgccggc cggtcatctg ttgttgttcc tgaccctggg ggtgctgtca 60

ctgctgctgc tcgtgaccgg ggcattcggt ttccacctgt ggagaaggca gtggcggtag 120

<210> 18
<211> 123
<212> DNA
<213> Homo sapiens

<400> 18
cattcccggc accgctacgc gctgattccg attcctctgg ccgtgatcac cacctgtatc 60

gtgctctaca tgaacggtat cctgaaatgc gacagaaagc ccgacaggac taacagcaat 120

tag 123

<210> 19
<211> 99
<212> DNA
<213> Rattus rattus

<400> 19
ccgctgtacc tgatcgtggg ggtgtcagcc ggcggtctgc tgctcgtgtt cttcggggca 60

ctgttcatct tctgcatttg caagaggaag aagcggtag 99

<210> 20
<211> 288
<212> DNA
<213> Homo sapiens

<400> 20
ccaccccggg cgtccgcact gccggcgccc cctaccggaa gcgcgctgcc cgatccgcaa 60

accgccagcg ccctgcctga cccgcccgcg gctagcgcct tgcctgccgc actggccgtg 120

atttcattcc tgctgggtct ggggctcggg gtggcctgcg tgttggcacg gactcagatc 180

aagaagctgt gctcctggag agacaaaaac tccgccgcct gtgtggtgta cgaggacatg 240

tcacactcga ggtgcaatac cctgtcctcg ccgaaccagt accagtag 288

<210> 21
<211> 23
<212> PRT
<213> Homo sapiens

<400> 21

Met Gly Trp Ser Cys Ile Met Leu Phe Leu Ala Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu
20

<210> 22
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Leader Exon1/Intron/Exon 2/TagsFLAG+Myc Tags

<400> 22

Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser Gly Glu Gln Lys Leu Ile
1 5 10 15

Ser Glu Glu Asp Leu
20

<210> 23
<211> 26
<212> PRT
<213> Homo sapiens

<400> 23

Met Asp Ile Arg Ala Pro Ala Gln Phe Leu Gly Ile Leu Leu Leu Trp
1 5 10 15

Phe Pro Gly Ala Arg Cys Asp Ile Gln Met
20 25

<210> 24
<211> 123
<212> PRT
<213> Escherichia coli

<400> 24

Gly Thr Pro Ala Val Thr Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr
1 5 10 15

Leu Lys Gly Glu Thr Thr Thr Lys Ala Val Asp Ala Glu Thr Ala Glu
20 25 30

Lys Ala Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly Val Trp
35 40 45

Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr Glu Val Asn Thr
50 55 60

Pro Ala Val Thr Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys
65 70 75 80

Gly Glu Thr Thr Thr Lys Ala Val Asp Ala Glu Thr Ala Glu Lys Ala
85 90 95

Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly Val Trp Thr Tyr
100 105 110

Asp Asp Ala Thr Lys Thr Phe Thr Val Thr Glu
115 120

<210> 25
<211> 207
<212> PRT
<213> Escherichia coli

<400> 25

Ile Asp Glu Ile Leu Ala Ala Leu Pro Lys Thr Asp Thr Tyr Lys Leu
1 5 10 15

Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala Val
20 25 30

Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn Asp Asn
35 40 45

Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr
50 55 60

Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser Glu Leu Thr Pro Ala
65 70 75 80

Val Thr Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys Gly Glu
85 90 95

Thr Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys
100 105 110

Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp
115 120 125

Ala Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala
130 135 140

Ser Glu Leu Thr Pro Ala Val Thr Thr Tyr Lys Leu Val Ile Asn Gly
145 150 155 160

Lys Thr Leu Lys Gly Glu Thr Thr Thr Lys Ala Val Asp Ala Glu Thr
165 170 175

Ala Glu Lys Ala Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly
180 185 190

Val Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr Glu
195 200 205

<210> 26
<211> 247
<212> PRT
<213> Escherichia coli

<400> 26

Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
1 5 10 15

Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln
20 25 30

Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn
50 55 60

Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu
65 70 75 80

Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro
85 90 95

Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala
100 105 110

Gln Ala Pro Lys Val Asp Gly Ser Gly Ser Gly Ser Gly Thr Pro Ala
115 120 125

Val Thr Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys Gly Glu
130 135 140

Thr Thr Thr Lys Ala Val Asp Ala Glu Thr Ala Glu Lys Ala Phe Lys
145 150 155 160

Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly Val Trp Thr Tyr Asp Asp

165 170 175

Ala Thr Lys Thr Phe Thr Val Thr Glu Val Asn Thr Pro Ala Val Thr
180 185 190

Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr
195 200 205

Thr Lys Ala Val Asp Ala Glu Thr Ala Glu Lys Ala Phe Lys Gln Tyr
210 215 220

Ala Asn Asp Asn Gly Val Asp Gly Val Trp Thr Tyr Asp Asp Ala Thr
225 230 235 240

Lys Thr Phe Thr Val Thr Glu
245

<210> 27
<211> 581
<212> PRT
<213> Escherichia coli

<400> 27

Ala Asn Ala Ala Gln His Asp Glu Ala Gln Gln Asn Ala Phe Tyr Gln
1 5 10 15

Val Leu Asn Met Pro Asn Leu Asn Ala Asp Gln Arg Asn Gly Phe Ile
20 25 30

Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Val Leu Gly Glu
35 40 45

Ala Gln Lys Leu Asn Asp Ser Gln Ala Pro Lys Ala Asp Ala Gln Gln
50 55 60

Asn Asn Phe Asn Lys Asp Gln Gln Ser Ala Phe Tyr Glu Ile Leu Asn
65 70 75 80

Met Pro Asn Leu Asn Glu Ala Gln Arg Asn Gly Phe Ile Gln Ser Leu
85 90 95

Lys Asp Asp Pro Ser Gln Ser Thr Asn Val Leu Gly Glu Ala Lys Lys
100 105 110

Leu Asn Glu Ser Gln Ala Pro Lys Ala Asp Asn Asn Phe Asn Lys Glu
115 120 125

Gln Gln Asn Ala Phe Tyr Glu Ile Leu Asn Met Pro Asn Leu Asn Glu
130 135 140

Glu Gln Arg Asn Gly Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln
145 150 155 160

```
Ser Ala Asn Leu Leu Ser Glu Ala Lys Lys Leu Asn Glu Ser Gln Ala
                165                 170                 175

Pro Lys Ala Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr
            180                 185                 190

Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Gly Phe
        195                 200                 205

Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala
    210                 215                 220

Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Ala Asp Asn Lys
225                 230                 235                 240

Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro
                245                 250                 255

Asn Leu Thr Glu Glu Gln Arg Asn Gly Phe Ile Gln Ser Leu Lys Asp
            260                 265                 270

Asp Pro Ser Val Ser Lys Glu Ile Leu Ala Glu Ala Lys Lys Leu Asn
        275                 280                 285

Asp Ala Gln Ala Pro Lys Glu Glu Asp Asn Asn Lys Pro Gly Asp Pro
    290                 295                 300

Arg Ile Ser Glu Ala Thr Asp Gly Leu Ser Asp Phe Leu Lys Ser Gln
305                 310                 315                 320

Thr Pro Ala Glu Asp Thr Val Lys Ser Ile Glu Leu Ala Glu Ala Lys
                325                 330                 335

Val Leu Ala Asn Arg Glu Leu Asp Lys Tyr Gly Val Ser Asp Tyr Tyr
            340                 345                 350

Lys Asn Leu Ile Asn Asn Ala Lys Thr Val Glu Gly Val Lys Ala Leu
        355                 360                 365

Ile Asp Glu Ile Leu Ala Ala Leu Pro Lys Thr Asp Thr Tyr Lys Leu
    370                 375                 380

Ile Leu Asn Gly Lys Thr Leu Lys Gly Glu Thr Thr Thr Glu Ala Val
385                 390                 395                 400

Asp Ala Ala Thr Ala Glu Lys Val Phe Lys Gln Tyr Ala Asn Asp Asn
                405                 410                 415

Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr
            420                 425                 430
```

Val Thr Glu Lys Pro Glu Val Ile Asp Ala Ser Glu Leu Thr Pro Ala
435 440 445

Val Thr Thr Tyr Lys Leu Val Ile Asn Gly Lys Thr Leu Lys Gly Glu
450 455 460

Thr Thr Thr Glu Ala Val Asp Ala Ala Thr Ala Glu Lys Val Phe Lys
465 470 475 480

Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly Glu Trp Thr Tyr Asp Asp
485 490 495

Ala Thr Lys Thr Phe Thr Val Thr Glu Lys Pro Glu Val Ile Asp Ala
500 505 510

Ser Glu Leu Thr Pro Ala Val Thr Thr Tyr Lys Leu Val Ile Asn Gly
515 520 525

Lys Thr Leu Lys Gly Glu Thr Thr Thr Lys Ala Val Asp Ala Glu Thr
530 535 540

Ala Glu Lys Ala Phe Lys Gln Tyr Ala Asn Asp Asn Gly Val Asp Gly
545 550 555 560

Val Trp Thr Tyr Asp Asp Ala Thr Lys Thr Phe Thr Val Thr Glu Met
565 570 575

Val Thr Glu Val Pro
580

<210> 28
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Gly/Ser linker

<400> 28

Gly Ser Gly Ser Gly Ser
1 5

<210> 29
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Gly/Ser Linker

<400> 29

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 30
<211> 81
<212> PRT
<213> Rattus rattus

<400> 30

Glu Met Val Ser Lys Pro Met Ile Tyr Trp Glu Cys Ser Asn Ala Thr
1 5 10 15

Leu Thr Cys Glu Val Leu Glu Gly Thr Asp Val Glu Leu Lys Leu Tyr
20 25 30

Gln Gly Lys Glu His Leu Arg Ser Leu Arg Gln Lys Thr Met Ser Tyr
35 40 45

Gln Trp Thr Asn Leu Arg Ala Pro Phe Lys Cys Lys Ala Val Asn Arg
50 55 60

Val Ser Gln Glu Ser Glu Met Glu Val Val Asn Cys Pro Glu Lys Gly
65 70 75 80

Leu

<210> 31
<211> 187
<212> PRT
<213> Rattus rattus

<400> 31

Ser Thr Ser Ile Thr Ala Tyr Lys Ser Glu Gly Glu Ser Ala Glu Phe
1 5 10 15

Ser Phe Pro Leu Asn Leu Gly Glu Glu Ser Leu Gln Gly Glu Leu Arg
20 25 30

Trp Lys Ala Glu Lys Ala Pro Ser Ser Gln Ser Trp Ile Thr Phe Ser
35 40 45

Leu Lys Asn Gln Lys Val Ser Val Gln Lys Ser Thr Ser Asn Pro Lys
50 55 60

Phe Gln Leu Ser Glu Thr Leu Pro Leu Thr Leu Gln Ile Pro Gln Val
65 70 75 80

Ser Leu Gln Phe Ala Gly Ser Gly Asn Leu Thr Leu Thr Leu Asp Arg
85 90 95

Gly Ile Leu Tyr Gln Glu Val Asn Leu Val Val Met Lys Val Thr Gln
100 105 110

Pro Asp Ser Asn Thr Leu Thr Cys Glu Val Met Gly Pro Thr Ser Pro
115 120 125

Lys Met Arg Leu Ile Leu Lys Gln Glu Asn Gln Glu Ala Arg Val Ser
130 135 140

Arg Gln Glu Lys Val Ile Gln Val Gln Ala Pro Glu Ala Gly Val Trp
145 150 155 160

Gln Cys Leu Leu Ser Glu Gly Glu Glu Val Lys Met Asp Ser Lys Ile
165 170 175

Gln Val Leu Ser Lys Gly Leu Asn Gln Thr Met
180 185

<210> 32
<211> 80
<212> PRT
<213> Homo sapiens

<400> 32

Met Lys Val Thr Gln Pro Asp Ser Asn Thr Leu Thr Cys Glu Val Met
1 5 10 15

Gly Pro Thr Ser Pro Lys Met Arg Leu Ile Leu Lys Gln Glu Asn Gln
20 25 30

Glu Ala Arg Val Ser Arg Gln Glu Lys Val Ile Gln Val Gln Ala Pro
35 40 45

Glu Ala Gly Val Trp Gln Cys Leu Leu Ser Glu Gly Glu Glu Val Lys
50 55 60

Met Asp Ser Lys Ile Gln Val Leu Ser Lys Gly Leu Asn Gln Thr Met
65 70 75 80

<210> 33
<211> 39
<212> PRT
<213> Homo sapiens

<400> 33

Ala Pro Gly Ala Leu Pro Ala Gly His Leu Leu Leu Phe Leu Thr Leu
1 5 10 15

Gly Val Leu Ser Leu Leu Leu Leu Val Thr Gly Ala Phe Gly Phe His
20 25 30

Leu Trp Arg Arg Gln Trp Arg
35

<210> 34
<211> 40

<212> PRT
<213> Homo sapiens

<400> 34

His Ser Arg His Arg Tyr Ala Leu Ile Pro Ile Pro Leu Ala Val Ile
1 5 10 15

Thr Thr Cys Ile Val Leu Tyr Met Asn Gly Ile Leu Lys Cys Asp Arg
20 25 30

Lys Pro Asp Arg Thr Asn Ser Asn
35 40

<210> 35
<211> 32
<212> PRT
<213> Rattus rattus

<400> 35

Pro Leu Tyr Leu Ile Val Gly Val Ser Ala Gly Gly Leu Leu Leu Val
1 5 10 15

Phe Phe Gly Ala Leu Phe Ile Phe Cys Ile Cys Lys Arg Lys Lys Arg
20 25 30

<210> 36
<211> 95
<212> PRT
<213> Homo sapiens

<400> 36

Pro Pro Arg Ala Ser Ala Leu Pro Ala Pro Pro Thr Gly Ser Ala Leu
1 5 10 15

Pro Asp Pro Gln Thr Ala Ser Ala Leu Pro Asp Pro Pro Ala Ala Ser
20 25 30

Ala Leu Pro Ala Ala Leu Ala Val Ile Ser Phe Leu Leu Gly Leu Gly
35 40 45

Leu Gly Val Ala Cys Val Leu Ala Arg Thr Gln Ile Lys Lys Leu Cys
50 55 60

Ser Trp Arg Asp Lys Asn Ser Ala Ala Cys Val Val Tyr Glu Asp Met
65 70 75 80

Ser His Ser Arg Cys Asn Thr Leu Ser Ser Pro Asn Gln Tyr Gln
85 90 95

<210> 37
<211> 93
<212> DNA
<213> Homo sapiens

<400> 37
gaattccttg aaaatggtgg gacatcctta tcagagaaaa cagttcttct gctggtgact 60

ccatttctgg cagcagcctg gagccttcat ccc 93

<210> 38
<211> 31
<212> PRT
<213> Homo sapiens

<400> 38

Glu Phe Leu Glu Asn Gly Gly Thr Ser Leu Ser Glu Lys Thr Val Leu
1 5 10 15

Leu Leu Val Thr Pro Phe Leu Ala Ala Ala Trp Ser Leu His Pro
20 25 30

<210> 39
<211> 90
<212> DNA
<213> Homo sapiens

<400> 39
accaatgcca caacaaaggc agcaggggga gcactccagt caacagcaag tttgtttgtc 60

gtgtcactga gtctcttgca tctttattca 90

<210> 40
<211> 30
<212> PRT
<213> Homo sapiens

<400> 40

Thr Asn Ala Thr Thr Lys Ala Ala Gly Gly Ala Leu Gln Ser Thr Ala
1 5 10 15

Ser Leu Phe Val Val Ser Leu Ser Leu Leu His Leu Tyr Ser
20 25 30

<210> 41
<211> 96
<212> DNA
<213> Homo sapiens

<400> 41
gtctcccagg tgaaaatttc aggagcccct accctctccc catccctcct gggtttgctg 60

ctgcccgcct ttggcattct cgtgtatctg gagttc 96

<210> 42
<211> 32
<212> PRT
<213> Homo sapiens

<400> 42

Val Ser Gln Val Lys Ile Ser Gly Ala Pro Thr Leu Ser Pro Ser Leu
1 5 10 15

Leu Gly Leu Leu Leu Pro Ala Phe Gly Ile Leu Val Tyr Leu Glu Phe
20 25 30

<210> 43
<211> 49
<212> DNA
<213> Homo sapiens

<400> 43
atggaatcac agacccaggt cctcatgttt cttctgctct gggtatctg 49

<210> 44
<211> 199
<212> DNA
<213> Homo sapiens

<400> 44
gtaagaaatt taaagtatta aaacctttc aaagtttcat ctttgtggta agaaatttgc 60

aatatgtgcc agtgtgtaat atttcttaca taataaattt gtgacagtat gataaggaca 120

tttaaatgaa aaatttcgac tgttgttata atctatgtct gtgtatctat gaattttcac 180

tgcctattaa ttattacag 199

<210> 45
<211> 11
<212> DNA
<213> Homo sapiens

<400> 45
gtgcctgtgc a 11

<210> 46
<211> 324
<212> DNA
<213> Homo sapiens

<400> 46
gacattcaga tgacccagtc tccatcctcc atgtctgtgt ctctgggaga cacagtcact 60

attacttgcc gggcaagtca ggacgttggg atttatgtaa actggttcca gcagaaacca 120

gggaaatctc ctaggcgtat gatttatcgt gcaacgaact tggcagatgg ggtcccatca 180

aggttcagcg gcagtaggtc tggatcagat tattctctca ccatcagcag cctggagtct 240

gaagatgtgg cagactatca ctgtctacag tatgatgagt atccattcac gttcggatcc 300

gggacgaagt tggaaataaa acgg 324

<210> 47
<211> 45
<212> DNA
<213> Homo sapiens

<400> 47
ggaggcggag gcagcggagg cggtggctcg ggaggcggag gctcg 45

<210> 48
<211> 348

<212> DNA
<213> Homo sapiens

<400> 48
caggtacagc tgaaagagtc aggacctggt ctggtgcagc cctcacagac cctgtctctc 60

acctgcactg tctctggact ctcattaatc agttatggtg taagttgggc tcgccagcct 120

ccagggaagg gtctggagtg gattgcagca atatcaagtg gtggaagcac atattataat 180

tcagttctca catctcgact gagcatcagc agggacacct ccaagagcca agttttctta 240

aaaatgaaca gtctgcaaac tgaagacaca gccatttact tctgtaccag agaactctgg 300

gactactatg attactgggg ccaaggagtc atggtcacag tctcctca 348

<210> 49
<211> 696
<212> DNA
<213> Rattus rattus

<400> 49
gctgaaacaa cagcccccag aaacccggga ggtgattgca agccttgtat atgtacaggc 60

tcagaagtat catctgtctt catcttcccc ccaaagccca aagatgtgct caccatcact 120

ctgactccta aggtcacgtg tgttgtggta gacattagcc aggacgatcc cgaggtccat 180

ttcagctggt ttgtagatga cgtggaagtc cacacagctc agactcgacc accagaggag 240

cagttcaaca gcactttccg ctcagtcagt gaactcccca tcctgcacca ggactggctc 300

aatggcagga cgttcagatg caaggtcacc agtgcagctt tcccatcccc catcgagaaa 360

accatctcca aacccgaagg cagaacacaa gttccgcatg tatacaccat gtcacctacc 420

aaggaagaga tgacccagaa tgaagtcagt atcacctgca tggtaaaagg cttctatccc 480

ccagacattt atgtggagtg gcagatgaac gggcagccac aggaaaacta caagaacact 540

ccacctacga tggacacaga tgggagttac ttcctctaca gcaagctcaa tgtgaagaag 600

gaaaaatggc agcagggaaa cacgttcacg tgttctgtgc tgcatgaagg cctgcacaac 660

caccatactg agaagagtct ctcccactcc cccggt 696

<210> 50
<211> 124
<212> DNA
<213> Mus musculus

<400> 50
aaagagcctc ctccatccac tgtctccaac atggcgaccg ttgctgttct ggttgtcctt 60

ggagctgcaa tagtcactgg agctgtggtg gcttttgtga tgaagatgag aaggagaaac 120

acag 124

<210> 51
<211> 178
<212> DNA
<213> Mus musculus

<400> 51
gtaggaaagg gcagagtctg agttttctct cagcctcctt tagagtgtgc tctgctcatc 60

aatggggaac acaggcacac cccacattgc tactgtctct aactgggtct gctgtcagtt 120

ctgggaactt cctagtgtca agatcttcct ggaactctca cagcttttct tctcacag 178

<210> 52
<211> 33
<212> DNA
<213> Mus musculus

<400> 52
gtggaaaagg aggggactat gctctggctc cag 33

<210> 53
<211> 172
<212> DNA
<213> Mus musculus

<400> 53
gttagtgtgg ggacagagtt gtcctgggga cattggagtg aagttggaga tgatgggagc 60

tctgggaatc cataatagct cctccagaga aatcttctag gtgcctgagt tgtgccatga 120

aatgaatatg tacatgtaca tatgcatata catttgtttt gttttaccct ag 172

<210> 54
<211> 83
<212> DNA
<213> Mus musculus

<400> 54
gctcccagac ctctgatctg tctctcccag attgtaaagg tgacactcta gggtctgatt 60

ggggaggggc aatgtggaca tga 83

<210> 55
<211> 20
<212> PRT
<213> Homo sapiens

<400> 55

Met Glu Ser Gln Thr Gln Val Leu Met Phe Leu Leu Leu Trp Val Ser
1 5 10 15

Gly Ala Cys Ala
20

<210> 56
<211> 108
<212> PRT
<213> Homo sapiens

<400> 56

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Met Ser Val Ser Leu Gly
1 5 10 15

Asp Thr Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Gly Ile Tyr
20 25 30

Val Asn Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Arg Arg Met Ile
35 40 45

Tyr Arg Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
65 70 75 80

Glu Asp Val Ala Asp Tyr His Cys Leu Gln Tyr Asp Glu Tyr Pro Phe
85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg
100 105

<210> 57
<211> 116
<212> PRT
<213> Homo sapiens

<400> 57

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Leu Ser Leu Ile Ser Tyr
20 25 30

Gly Val Ser Trp Ala Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Ala Ile Ser Ser Gly Gly Ser Thr Tyr Tyr Asn Ser Val Leu Thr
50 55 60

Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Ala Ile Tyr Phe Cys Thr
85 90 95

Arg Glu Leu Trp Asp Tyr Tyr Asp Tyr Trp Gly Gln Gly Val Met Val
100 105 110

Thr Val Ser Ser
115

<210> 58
<211> 232
<212> PRT
<213> Rattus rattus

<400> 58

Ala Glu Thr Thr Ala Pro Arg Asn Pro Gly Gly Asp Cys Lys Pro Cys

1 5 10 15

Ile Cys Thr Gly Ser Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys
20 25 30

Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val
35 40 45

Val Val Asp Ile Ser Gln Asp Asp Pro Glu Val His Phe Ser Trp Phe
50 55 60

Val Asp Asp Val Glu Val His Thr Ala Gln Thr Arg Pro Pro Glu Glu
65 70 75 80

Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Leu His
85 90 95

Gln Asp Trp Leu Asn Gly Arg Thr Phe Arg Cys Lys Val Thr Ser Ala
100 105 110

Ala Phe Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Pro Glu Gly Arg
115 120 125

Thr Gln Val Pro His Val Tyr Thr Met Ser Pro Thr Lys Glu Glu Met
130 135 140

Thr Gln Asn Glu Val Ser Ile Thr Cys Met Val Lys Gly Phe Tyr Pro
145 150 155 160

Pro Asp Ile Tyr Val Glu Trp Gln Met Asn Gly Gln Pro Gln Glu Asn
165 170 175

Tyr Lys Asn Thr Pro Pro Thr Met Asp Thr Asp Gly Ser Tyr Phe Leu
180 185 190

Tyr Ser Lys Leu Asn Val Lys Lys Glu Lys Trp Gln Gln Gly Asn Thr
195 200 205

Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu
210 215 220

Lys Ser Leu Ser His Ser Pro Gly
225 230

<210> 59
<211> 79
<212> PRT
<213> Mus musculus

<400> 59

Lys Glu Pro Pro Pro Ser Thr Val Ser Asn Met Ala Thr Val Ala Val
1 5 10 15

```
Leu Val Val Leu Gly Ala Ala Ile Val Thr Gly Ala Val Val Ala Phe
            20                  25                  30

Val Met Lys Met Arg Arg Arg Asn Thr Gly Gly Lys Gly Gly Asp Tyr
        35                  40                  45

Ala Leu Ala Pro Gly Ser Gln Thr Ser Asp Leu Ser Leu Pro Asp Cys
    50                  55                  60

Lys Gly Asp Thr Leu Gly Ser Asp Trp Gly Gly Ala Met Trp Thr
65                  70                  75
```